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ABSTRACT OF DISSERTATION 
TOWARDS THE PREDICTION OF MUTATIONS IN GENOMIC SEQUENCES 
by 
Juan Carlos Martinez 
Florida International University, 2013 
Professor Sundaraja Sitharama Iyengar, Major Professor 
Bio-systems are inherently complex information processing systems. Furthermore, 
physiological complexities of biological systems limit the formation of a hypothesis in 
terms of behavior and the ability to test hypothesis. More importantly the identification 
and classification of mutation in patients are centric topics in today’s cancer research. 
Many cancers have been traced to somatic mutations in different genes in the genome. 
Classification of cancer based on gene expression has provided insights into its complex 
landscape of multiple interactions between gene networks, as well as into possible 
treatment strategies. Next generation sequencing (NGS) technologies can provide 
genome-wide coverage at a single nucleotide resolution and at reasonable speed and cost. 
The unprecedented molecular characterization provided by NGS offers the potential for 
an individualized approach to treatment. These advances in cancer genomics have 
enabled scientists to interrogate cancer-specific genomic variants and compare them with 
the normal variants in the same patient. Analysis of this data provides a catalog of 
somatic variants, present in tumor genome but not in the normal tissue DNA. 
Determining the molecular signatures of genes mutated in cancer may help to predict the 
clinical outcome and carry out therapeutic modifications in treating the patients. 
However, predicting such signatures at the time of the tumor discovery is a major 
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challenge. Several groups have reported lists of predictive genes and reported good 
predictive performance in terms of prognosis and potential for malignancy based on 
them. However, the gene lists differed widely and had only very few genes in common. 
The search for reliable molecular signatures has provided a fertile field for computational 
approaches. In this dissertation, we present a new computational framework to the 
problem of predicting the number of mutations on a chromosome for a certain patient, 
which is a fundamental problem in clinical and research fields. We begin this dissertation 
with the development of a framework system that is capable of utilizing published data 
from a longitudinal study of patients with acute myeloid leukemia (AML), who’s DNA 
from both normal as well as malignant tissues was subjected to NGS analysis at various 
points in time. By processing the sequencing data at the time of cancer diagnosis using 
the components of our framework which includes training mutations data, mutation 
extractions, normalization, subspace-based instance filtering, etc., we tested our 
framework by predicting the regions of the genome to be mutated at the time of relapse 
and, later, by comparing our results with the actual regions that showed mutations 
(discovered by sequencing their genomes at the time of relapse). We demonstrate that this 
coupling of the algorithm pipeline can drastically improve the predictive abilities of 
searching a reliable molecular signature. Arguably, the most important result of our 
research is its superior performance to other methods like Radial Basis Function 
Network, Sequential Minimal Optimization, and Gaussian Process. In the final part of 
this dissertation, we present a detailed significance, stability and statistical analysis of our 
model. A comparison performance of the results are presented. This work clearly lays a 
good foundation for future research for other types of cancer.  
viii 
 
TABLE OF CONTENTS 
CHAPTER                        PAGE 
 
1. INTRODUCTION ...........................................................................................................1 
2. LITERATURE REVIEW ................................................................................................4 
2.1 Background ....................................................................................................................4 
2.1.1 Bioinformatics .............................................................................................................5 
2.1.2 The DeoxyriboNucleic Acid  (DNA) ..........................................................................5 
2.1.3 Genes ...........................................................................................................................7 
2.1.4 Gene expression ..........................................................................................................7 
2.1.5 DNA Mutations .........................................................................................................10 
2.1.6 Cancer Genomics Study ............................................................................................17 
2.2 Related Work. ..............................................................................................................20 
2.2.1 Fasta ..........................................................................................................................20 
2.2.2 Blast ..........................................................................................................................21 
2.2.3 RepeatMasker ...........................................................................................................21 
2.2.4 Masker Aid ................................................................................................................21 
2.2.5 Tandem repeat finder ................................................................................................22 
2.2.6 Reputer ......................................................................................................................23 
2.2.7 The Vmatch large scale sequence analysis software ................................................23 
2.2.8 Amadeus ...................................................................................................................23 
2.2.9 Allegro  .....................................................................................................................24 
2.2.10 Our work .................................................................................................................24 
2.2.11 Comparative chart ...................................................................................................24 
2.2.12 Other studies on cancer genomics ...........................................................................25 
2.2.13 Clinical perspective .................................................................................................35 
3. RESEARCH PROBLEM AND SPECIFIC AIMS ........................................................39 
3.1 Motivation ....................................................................................................................39 
3.2 Problem definition .......................................................................................................40 
3.3 Specific Aims ...............................................................................................................41 
3.3.1 Aim # 1: To build a tool for statistical analysis on genomic data sets. .....................41 
3.3.2 Aim # 2: To utilize this data set and formulate a prediction model. .........................41 
3.3.3 Aim # 3: To facilitate the discovery of new functionalities in areas of the genome 
that had not been previously implicated in cancer. ............................................................41 
3.4 Significance and impact of our work ...........................................................................43 
 
4. DATA MINING AND STATISTICAL ANALYSIS ....................................................45 
4.1 Background ..................................................................................................................45 
4.2 Weka  ...........................................................................................................................45 
4.2.1 Dataset .......................................................................................................................46 
4.2.2 Classifier ...................................................................................................................47 
ix 
 
4.2.3 Weka from Java – API ..............................................................................................47 
4.3 Statistical Analysis .......................................................................................................47 
 
5. MODELING CANCER RELATED GENOME SEQUENCES OF PATIENT DATA 50 
5.1 Introduction ..................................................................................................................50 
5.2 Statistical analysis for our model .................................................................................50 
5.3 Mechanisms and Models ..............................................................................................52 
 
6. MATERIALS AND METHODS ...................................................................................56 
6.1 Framework ...................................................................................................................57 
6.2 Patient data ...................................................................................................................57 
6.3 Variables to consider ....................................................................................................62 
6.4 Prediction model ..........................................................................................................63 
 
7. RESULTS ......................................................................................................................67 
7.1 Prediction of number of mutations per chromosome. ..................................................67 
7.1.1 Significance of our experimental data ......................................................................68 
7.1.2 Analysis of performance measures to evaluate the success of our prediction ..........77 
7.1.3 Significance, stability and statistical analysis of model ............................................79 
7.1.4 Comparison of performance of our model versus other algorithms .........................94 
7.1.5 Concluding Remarks .................................................................................................98 
7.2 Prediction of location of mutations. ...........................................................................100 
7.3 Accuracy discussion ...................................................................................................102 
 
8. CONCLUSION ............................................................................................................105 
8.1 Research summary .....................................................................................................105 
8.2 Final statistical remarks .............................................................................................107 
8.3 Foundation for further discoveries. ............................................................................109 
8.4 Application of our framework in the treatment of patients by clinical oncologists ...110 
8.5 Some potential enhancements. ...................................................................................112 
 
SPECIAL RECOGNITIONS ...........................................................................................113 
 
APPENDICES .................................................................................................................114 
 
BIBLIOGRAPHY ............................................................................................................143 
 
VITA ................................................................................................................................153 
  
 
 
 
x 
 
LIST OF TABLES 
TABLE          PAGE 
Table 2.1. Examples of genetic diseases caused by expanding    14 
tri-nucleotide repeats.    
 
Table 2.2. Pathologic intronic insertions in humans.     16 
Table 2.3. Comparative chart of our work versus other approaches.  25 
Table 2.4.  Comparison of Wavelet Analysis and Fourier transform (FT).  30 
Table 6.1. Patient designation, gender and age.                      59 
Table 7.1. Number of mutations per chromosome in patient UPN 933124. 68 
Table 7.2. Table for performance measures for our prediction model.  79 
Table 7.3. Statistical analysis of errors for patient A.    81 
Table 7.4. Statistical analysis of errors for patient B.    81 
Table 7.5. Statistical analysis of errors for patient C.    82 
Table 7.6. Statistical analysis of errors for patient D.    82 
Table 7.7. Statistical analysis of errors for patient E.    83 
Table 7.8. Statistical analysis of errors for patient F.    
 83 
Table 7.9. Statistical analysis of errors for patient G.    84 
Table 7.10. Statistical analysis of errors for patient H.    84 
Table 7.11. Statistical analysis of all Patients.     85 
Table 7.12. Coefficients for chromosome models for patient A.   86 
Table 7.13. Coefficients for chromosome models for patient B.   87 
Table 7.14. Coefficients for chromosome models for patient C.   88 
xi 
 
Table 7.15. Coefficients for chromosome models for patient D.   89 
Table 7.16. Coefficients for chromosome models for patient E.   90 
Table 7.17. Coefficients for chromosome models for patient F.   91 
Table 7.18. Coefficients for chromosome models for patient G.   92 
Table 7.19. Coefficients for chromosome models for patient H.   93 
Table 7.20. Comparison table for correlation coefficients    97 
for our model versus others. 
 
Table 7.21. Location of mutations, both observed and predicted   102 
for patient UPN 933124.   
 
Table 7.22. Summary of results for patient UPN 933124.    103 
xii 
 
LIST OF FIGURES 
FIGURE           PAGE 
Figure 2.1. Graphical representation of a DNA double helix.   6 
Figure 2.2. Mechanism for gene expression.      8 
Figure 2.3. Transcription process carried out by DNA     10 
polymerase. Blue bases: RNA product. 
 
Figure 2.4. Transcription from DNA to RNA example     10 
and translation to protein. 
 
Figure 2.5. DNA Mutation.        11 
Figure 2.6. Types of DNA mutations.      12 
Figure 2.7. Tandem repeat example.       13 
Figure 2.8. Transposable element example.      15 
Figure 2.9. Sample procedure of applying wavelet transform    28 
in cancer genome analysis. 
 
Figure 2.10. The four types of mutations.      31 
Figure 6.1. Dependency flow graph for our prediction framework.   58 
Figure 6.2. Sample data files for patient UPN 933124.    62 
Figure 6.3. Overview of geneMap.txt.      62 
Figure 6.4. Weka input file.        64 
Figure 6.5 Algorithm for finding mutations locations.    66 
Figure 7.1 Histogram of absolute error for patient A.    69 
Figure 7.2 Histogram of absolute error for patient B.    69 
Figure 7.3 Histogram of absolute error for patient C.    70 
Figure 7.4 Histogram of absolute error for patient D.    70 
xiii 
 
Figure 7.5 Histogram of absolute error for patient E.    71 
Figure 7.6 Histogram of absolute error for patient F.    71 
Figure 7.7 Histogram of absolute error for patient G.    72 
Figure 7.8 Histogram of absolute error for patient H.    72 
Figure 7.9 Histogram of relative error for patient A.    73 
Figure 7.10 Histogram of relative error for patient B.    73 
Figure 7.11 Histogram of relative error for patient C.    74 
Figure 7.12 Histogram of relative error for patient D.    74 
Figure 7.13 Histogram of relative error for patient E.    75 
Figure 7.14 Histogram of relative error for patient F.    75 
Figure 7.15 Histogram of relative error for patient G.    76 
Figure 7.16 Histogram of relative error for patient H.    76 
Figure 7.17 Comparison of performance of our model versus others.  98 
Figure 7.18 Potential estimation error graph as more data is obtained.  100 
 
 
 
 
xiv 
 
ACRONYMS AND ABBREVIATIONS 
DNA   Deoxyribonucleic Acid 
A,C,T,G Adenine (A), cytosine (C), guanine (G), and thymine (T) 
RNA   Ribonucleic Acid 
mRNA Messenger RNA 
TR    Tandem Repeat 
TE   Transposable Element 
NCBI   National Center for Biotechnology Information 
NGS   Next Generation Sequencing 
OO    Object Oriented 
ML   Machine Learning 
IDE   Integrated Development Environment 
JDK   Java Development Kit 
 
 
1 
 
CHAPTER 1 
INTRODUCTION 
 
In academia, as well as in industry, there have been a number of efforts in developing 
computer algorithms to aid the research in molecular biology. Due to the fact that both 
DNA and proteins can be directly represented as a sequence of characters (either bases or 
aminoacids, respectively), the bioinformatics field has come up with a large number of 
computer solutions with a strong emphasis on string algorithms. A significant number of 
studies has shown that cancer development brings about changes in DNA molecule at a 
nucleotide level (mutations) within the genome of an individual. 
Many cancers have been traced to somatic mutations in different genes in the genome. 
[1]. The classification of cancer based on gene expression has provided much insight into 
the complex landscape of multiple interactions between gene networks, as well as into 
possible treatment strategies. Advances in cancer genomics have been accelerated with 
the emergence of high-throughput sequencing strategies that enable scientists to 
interrogate cancer-specific genomic variants and compare them with the normal variants 
in the same patient [2][3]. Next generation  sequencing (NGS) technologies can provide 
genome-wide coverage at a single nucleotide resolution and at reasonable speed and cost. 
[4]. The unprecedented molecular characterization provided by NGS offers the potential 
for an individualized approach to treatment. 
One of the contributions of such strategies includes the definition of relatively 
characteristic gene expression profiles, or molecular signatures that may have prognostic 
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implications for targeted therapies. In cancer patients, the objective of NGS is to obtain 
and compare information about cancer and normal tissue DNAs. Analyses of the data 
provide a catalog of somatic variants present in tumor genome but not in the normal 
tissue DNA. The goal of the analysis is to reveal a putative drug target in the examined 
cancer which facilitates the selection of therapy, and improves the personalized risk 
assessment. Moreover, determining the molecular signatures of genes mutated in cancer 
may help to predict the clinical outcomes [5]. 
Predicting molecular signatures based on the initial events in cancer development may 
help researchers, as well as clinicians, to carry out therapeutic modifications in treating 
the patients. However, predicting such signatures at the time of the tumor diagnosis is a 
major challenge. Several groups have reported lists of predictive genes and reported good 
predictive performance in terms of prognosis and potential for malignancy based on 
them. However, the gene lists differed widely and had only very few genes in common. 
Furthermore, those types of predictions were based on computational approaches not 
involving NGS, such as microarray analysis, qPCR, and others [6][7][8] in various types 
of cancer such as colorectal [9], lung [10], prostate[11], breast cancer[12] and others. 
Additionally, the disadvantages of current predictive models in cancer are that they are 
focused on evaluating mutations that anticipate the risk of progression and its clinical 
impact on the length of patient’s survival. They are not intended to predict mutational 
events at molecular level, rather to detect and classify existing mutations, and utilize that 
information to make predictions in the behavior of the cancer disease.  
In our work, by having the full sequence of the genome from both normal and cancer 
tissue at various points in time, we are able to extract valuable information to validate the 
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predictions generated from the genome. Thus, we propose to search for longitudinal 
studies of cancer patients with such identified mutated genes by the use of NGS at 
different points in time. The mutation profile identified earlier in time will serve as the 
basis for the prediction later in time. Furthermore, we will compare the observed mutated 
locations at the time of relapse with the results of our own predictions. 
Our goal in this study was to test a computational framework utilizing published data 
from a longitudinal study [13] of patients with acute myeloid leukemia (AML) whose 
DNA from both normal as well as cancer tissues were subjected to next generation 
sequencing analysis at various points in time. First of all, we processed the longitudinal 
sequencing data from cancer tissue. Secondly, we tested our framework by predicting the 
regions of the genome to mutate at the time of relapse. Finally, we compared our results 
with the observed mutated regions, identified by sequencing their genomes at the time of 
relapse. The accuracy of the predicted number of mutations ranged from 75 to 84%; the 
accuracy of the locations of mutations ranged from 69% to 88% in the patients analyzed. 
Our predictions agree well with the reported data. Although our approach is purely 
computational and does not provide insights into the putative molecular mechanisms by 
which the mutations occur, we are confident that it may assist researchers in determining 
the importance of a particular mutation in cancer progression, thus providing another tool 
to select candidates to target in drug development for cancer treatment. 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Background 
Over time our knowledge of genomes has developed at the same rate as their sequencing. 
Furthermore, sequencing capacity has grown significantly recently. The characterization 
of the genome starts from its sequencing or reading step and assembling. However, it 
does not end by the time its sequence is obtained. Thus, at this point, we are just at the 
beginning of a much more complex study. We are constantly looking for better coverage 
of the sequence and better resolution and, as a result, the assembly of the human genome 
is a multistep always-evolving process. The Genome Reference Consortium frequently 
produces a new version of the human reference genome for scientists to have a unique set 
of gene coordinates when comparing their results. The latest release from GRC is the 37th 
[14].  With every new release, a large set of analysis is required to understand the works 
of the genome, its functionalities, and how we can detect any anomalies in it as well as 
how we can predict future ones. 
Nevertheless, before going into further details of how to understand the scope of our 
research of the genome, it is necessary to have a minimum background on how it works 
[111]. In the next pages, we will provide some basic concepts in the Biology field that 
will ease the understanding of the rest of the work. This dissertation was written for 
readers who do not necessarily have the biology background, and, as result, a minimal 
background is provided. 
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2.1.1 Bioinformatics 
Bioinformatics is a compound word that consists of two root words. The first word “bio” 
indicates we are dealing with problems that originate from biology. The second word 
“informatics” indicates that the problems are to be solved by the discipline that works on 
the management of information and the design of computational algorithms, namely, 
computer science. 
 
2.1.2 The DeoxyriboNucleic Acid  (DNA) 
The DeoxyriboNucleic Acid (DNA) [16][17] plays the role of the information archive for 
all organisms. DNA molecules present a double helix structure containing four-letter 
bases which stand for the 4 nucleotides. These four nucleotides are adenine (A), cytosine 
(C), guanine (G), and thymine (T). Nucleotides belong to two types: purines and 
pyrimidnes. Adenine and guanine fall into the first category while cytosine and thymine 
into the second one.  
DNA is not normally present as a single long molecule but as an associated pair of 
molecules. DNA strands present the shape of a double helix as can be seen in Figure 2.1. 
Alternating phosphate and sugar elements compose the backbone of a DNA strand. The 
direction of the nucleotides in one strand is always opposite to the direction from the 
other. As a result, we consider DNA strands as anti-parallel. These DNA strands are 
asymmetric and known as 5' and 3' and follow a direction from one to the other. All bases 
on one strand form a bond with specifically one type of base on the other strand. We call 
this behavior complementary base pairing. Thus, purines form hydrogen complement  
with pyrimidines: A with T (A=T or T=A), and C with G (C=G or G=C). When two 
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nucleotides are bound together across the DNA strands form base pair (bp).  
The DNA presents a double stranded helix with complimentary information on each 
strand. This characteristic is of the DNA is vital in the functionality of the DNA for all 
living beings [18]. DNA has mechanisms for self-replication and for translation of genes 
into proteins. Furthermore, replications are necessary for the stability of the inheritance. 
However, some imperfect replications are also necessary for evolution. Genetic 
information is implemented by the synthesis of mRNA (messenger RNA) into proteins. 
Proteins are molecules in charge of the structure and activities of living beings. 
Antibodies, produced by our own organisms, to fight disease, along with some enzymes 
and muscle tissue belong to the protein category.  Proteins can be composed of 200-400 
amino acids long, requiring 600-1200 DNA bases. Surprisingly, only a small percentage 
of the total sequence genome encodes for proteins. There are vast areas of the DNA 
sequence which account for control mechanisms, and others for which no functionality 
has been discovered yet, and, therefore, considered as “junk". However, it might not 
necessarily be junk as there have been discoveries of transposable elements that have a 
regulatory function in this area, leaving us with more to be discovered in these areas 
[19][20].  
 
Figure 2.1. Graphical representation of a DNA double helix. [111] 
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2.1.3 Genes 
Our main unit of heredity for all organisms is called a gene. Genes keep the necessary 
information to build and transfer genetic traits to descendants as well as to maintain cells. 
Simply speaking, a gene can be seen as a segment of nucleic acid that, when considered 
as a whole, specifies a trait. Genes can be mapped to multiple biological traits such as 
such as eye or hair color.  
Genes have coding sequences or exons and non-coding sequences or introns. If a gene is 
active, both exons and introns are copied though transcription, producing as an output an 
RNA copy of the information from the gene. The output allows for protein synthesis from 
genetic code. The molecules that are produced from gene expression are called gene 
products and are the ones that make it possible for organisms to develop proper 
functionality.. Gerstein et al. [21] provide a precise definition of a gene: “A gene is a 
union of genomic sequences encoding a coherent set of potentially overlapping functional 
products". Besides the regions that code for protein, genes also have regulatory regions as 
can be seen in Figure 2.2.  
Regulatory regions include enhancers that are responsible for compensating for a weak 
promoter [22]. Small RNAs consist of short sequences roughly between 18 and 25 bases. 
They act as regulators of stability or availability for translation of RNAs. 
 
2.1.4 Gene expression 
When a gene is expressed, the products obtained from it are often proteins. Gene 
expression is a widely used process for all organisms ranging from the most basic ones to 
the most complex and developed ones.  
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Gene regulation allows cell function and control over structure and, as a result, is the base 
for cellular differentiation and adaptability. Gene expression is the main level where the 
genotype gives rise to the phenotype. Thus, genetic code can be interpreted. 
 
 
Figure 2.2. Mechanism for gene expression. [15] 
 
Gene expression is divided into 5 steps: 
 
i. Transcription 
The gene acts as a blueprint for the production of RNA. We call transcription to the 
RNA's production copies of the DNA. It is done by RNA polymerase by adding one 
RNA nucleotide at a time to a growing RNA strand as can be observed in Figure 2.3. 
RNA complementarity to DNA is present here. For instance, a T in the DNA will 
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produce an A in the RNA. Nevertheless, in RNA the Uracil is obtained instead of 
Thymine in place of an Adenine in the DNA strand. For instance, the mRNA complement 
of a DNA strand piece "CAT" would be transcribed as "GUA". Figure 2.4 shows more on 
this. 
 
ii. RNA processing 
Even though, it is not the only, splicing to remove introns is the most common RNA 
processing.  
 
iii. RNA export 
In eukaryotes, mature RNA has to be exported out of the nucleus to the cytoplasm which 
is where proteins actually work [15]. 
 
iv. Translation 
Every RNA triplet has a corresponding binding site for amino acids which are chained 
together by the ribosome. The ribosome produces a structure-less protein out of the by 
taking the amino acid from each transfer RNA. The second step of the Figure 2.4 
illustrates this process. 
 
v. Folding 
Here, the recently formed unfolded polypeptide will proceed to fold into the functional 3-
dimensional structure. 
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After this process, the protein working into the cell or transported outside of it as it 
occurs in digestive enzymes. 
 
 
 
Figure 2.3. Transcription process carried out by DNA polymerase. Blue bases: RNA 
product.[15] 
 
 
Figure 2.4. Transcription from DNA to RNA example and translation to protein. [15] 
 
2.1.5 DNA Mutations 
We define DNA mutations as the sequences that appear within a genome that do not 
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comply with what is "expected" in that location. The human DNA is very similar from 
individual to individual with minor differences in the nucleotides that appear in the 
genome. Nevertheless, when these differences are not minor and become major 
differences, different implications may occur in the individual affecting his health and/or 
capabilities.  
Germinal mutations are the ones and individual is born with. Somatic mutations happen 
during one's lifetime and are studied by looking at tumor cells and normal cells from the 
same patient at different times. 
Figure 2.5 and Figure 2.6 show graphically how a mutation occurs within the DNA. This 
mutation can be of the form of a replacement, deletion or insertion of bases within the 
genome. 
 
 
Figure 2.5. DNA Mutation. [23] 
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Figure 2.6. Types of DNA mutations. [24] 
 
Many of these mutations are present since birth and many others are acquired during the 
development of a disease such as cancer.  
These mutations have different forms and appear in different locations within the DNA. 
These mutations act as repeat sequences following a specific pattern or not. The two 
major types of repeat sequences are tandem repeats (TRs) including micro-satellites, 
mini-satellites, and satellites, and transposable elements (TEs), which are dispersed 
within genomes with a moderate to high degree of repetitiveness. 
 
i. Tandem Repeats (TRs) 
A common feature for both eukaryotic and prokaryotic genomes [25][26][27] is the 
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repetition of both large and short sequences (2 to several hundred nucleotides long), 
known as tandem repeats. Many experts suggest that as much as 50% of the human 
genome is composed of repetitions [28]. 
An example of a tandem repeat is illustrated in Figure 2.7:  
 
 
Figure 2.7. Tandem repeat example. 
The biological role of repeated sequences has been researched by a number of scientists 
who have determined that they are linked to evolutionary mechanisms in prokaryotic 
organisms [29]. Tandem repeats [30][31] are common in eukariotyc organisms, as well. It 
has been reported that tandem repeats are responsible for over 30 inherited diseases in 
humans. Tri-nucleotide expansions have been associated with fragile X syndrome, 
myotonic dystrophy, Huntington’s disease, various spino-cerebellar ataxias, Friederich’s 
ataxia and others. Tandem repeats can exist in coding as well as in non-coding DNA. 
Expansion found in coding regions can affect the function of the genes involved by 
disrupting the normal synthesis of the proteins. When these repeats appear inside non-
coding regions, it has been shown to affect gene expression via alterations in the 
transcription levels of the gene  when the affected area correspond to either a promoter 
region, or a region containing factors that affect protein translation. Table 2.1 clearly 
illustrates genetic diseases related to Tandem Repeats. 
Unfortunately, individuals suffering from inherited diseases do not have many choices in 
terms of treatment. However, in some cases an early diagnosis may help to ameliorate the 
devastating effects of the disease. Current tools available in clinics, as well as in 
ACTACTACTACT 
 Tandem repeat of 3 bases and length 4 
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bioinformatics allow the medical community to carry out diagnostics as early as in the 
pre-implantation embryo, to determine whether the embryo carry the expansions 
associated with a given disease or not.  
Expansion of DNA repeats are not limited to inherited disorders only. Depending on the 
length of the repeat and the area it spans, tandem repeats are also known as “satellite, 
mini-satellite, and microsatellite” DNA. Blanes and Diaz-Cano [32], present a 
complementary analysis of microsatellite tumor profile in which they observe that 
changes in the number of repeats occur depending on the progression in the cancer cell, 
compared with the normal tissue. Multiple studies have shown micro- and mini-satellite 
instability during cancer progression in a wide variety of tumors, both familiar and 
sporadic. Breast and ovarian cancers show many more tandem duplications than other 
tumor types [33]. 
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Table 2.1. Examples of genetic diseases caused by expanding tri-nucleotide repeats. [34] 
ii. Transposable Elements (TEs) 
Transposable elements are mobile within the genome, and as such, they can be inserted 
anywhere, whether within the coding region of a gene, or within intronic regions. As a 
result of their insertion the expression of a gene is affected by changing the protein coded 
by the gene where insertion occurred, or by disrupting the natural context of the gene if 
the insertion occurred within an intronic region. The term "normal" context refers to the 
regions that surround the gene, meaning upstream and downstream regions that contain 
controlling elements, such as promoters, enhancers and inhibitors of gene expression. If 
the insertion occurred within any of those controlling elements, the gene expression 
would change. An example of a transposable element is illustrated in Figure 2.8. 
 
  
Figure 2.8. Transposable element example. 
 
We have to keep in mind that whether an insertion or modification of sub-sequence 
within a genome is considered a mutation event, whether one base or 300 bases, or more. 
 
Table 2.1 shows the result of repeats affecting coding regions. Additionally, there are also 
reports of inherited and non-inherited diseases, including various types of cancer, 
associated with repeats in non-coding regions. Table 2.2 illustrates such scenarios as well 
and shows reports regarding transposable repeats, or transposable elements repeats 
related to genome mutations. 
...ACTCCTTAAACTCGGTACTGGGGC... 
Transposable element: ACT 
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Table 2.2. Pathologic intronic insertions in humans. [35]
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2.1.6 Cancer Genomics Study 
The understanding of the genetic basis of disease in general, and of cancer in particular, 
has progressed dramatically in the past few decades. Several factors have been involved 
in that progress: some, purely of biological nature, and some at the intersection between 
biology and computational sciences. The science of genetics began in the 1860’s when 
Gregor Mendel studied inheritance in pea plants (Pisum sativum) [36]. In the 1940’s 
Oswald Avery, Colin MacLeod, and Maclyn McCarty showed DNA was the genetic 
material [37][38]. In 1953 James Watson and Francis Crick proposed the double-helix 
model for the structure of DNA [39]. The Human Genome Project (HGP) began in 1990 
and was completed in 2003 by the International Human Genome Sequencing Consortium 
[40][41][42]. The reference genome produced by the HGP came from a single 
anonymous male donor from Buffalo, New York [43]. Since then, a number of 
international projects have started to elucidate the genomic sequence of various 
individuals. For instance, the HapMap Project which used DNA samples from 270 
individuals, the 1000 Genomes Project, the Cancer Genome Atlas, the Cancer Genome 
Anatomy Project, and the Cancer Genome Characterization Initiative [36].  
The Cancer Genome Atlas (TCGA) is a program supported by the National Institutes of 
Health (NIH). It will help to understand what turns a normal cell into a cancer cell. Its 
main approach as stated in its web site (cancergenome.nih.gov) is to compare DNA from 
normal and cancer tissue to find what are the differences. By utilizing such approach 
scientists working within the TCGA Project have learned that there are certain areas of 
the genome commonly affected in several types of cancers. Often these changes affect 
genes that control pathways in cells that cause cells to divide and survive when they 
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normally would die. Another finding is that specific changes –also called signatures- 
allow scientists to tell one type of cancer from another. These signatures help doctors 
identify specific “types of cancer” which may respond differently to various treatments or 
have different prognosis. In order to better understand these concept I would like to 
define some of the specialized terminology (see cancergenome.nih.gov) 
The genome is given by all the DNA that exists within a cell. For the majority of cells, 
the genome is wrapped into two sets of chromosomes inherited from both parents. These 
chromosomes consist of six billion DNA letters. The genetic alphabet consists of 4 
letters: A, C, G and T. The area of Genomics consists of studying how these letters 
appear in a sequence and how every string of letters passes the information to the 
proteins, the real building blocks in the organism. DNA stands for deoxyribonucleic acid 
and instructions encoded in the string of DNA are passed to the proteins. 
For cancer cells, changes in the bases (A,C,T, and G) can cause a modify the meaning of 
a genomic “word” or “sentence”. These changes in the bases can make the cell to produce 
a protein that does not allow the cell to work as expected. These proteins could make the 
cell grow faster than normal and affect neighboring cells. The accumulation of these 
changes, or mutations, within a cell leads to the development of cancer. Mutations are 
classified as germ line and somatic. Germ line mutations affect germinal cells (oocytes or 
spermatocytes) and are transmitted to the offspring. Somatic mutations, on the contrary, 
affect somatic cells and are not transmitted to the offspring. The study of the genome in a 
cancer cell is known as cancer genomics. The field of cancer genomics has had a 
profound impact in the understanding of cancer progression at a molecular level. The 
field itself has been dramatically impacted by the application of the so called next-
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generation sequencing, or NGS, technologies, which has accelerated the pace of 
discovery, while reducing the cost. NGS technologies greatly depend on computer power 
to acquire, process, and analyze the data coming from sequencing the genomes of 
healthy, as well as cancer cells [44]. The importance of studies made at the intersection of 
cancer biology and computer sciences can be never be understated. As data generated 
from multiple sequencing projects grows, the computer capabilities should keep up with 
the challenges of analyzing the terabyte amounts of data. The strongest contribution of 
NGS on cancer genomics has been the ability to re-sequence, analyze and compare the 
matched tumor and normal genome of a single patient [44].  
Finally, the sequence of the human genome and the discoveries brought about by it, or 
related to it, have allowed the faster integrations of genomics into the medical practice 
[45]. As cancer is defined as a genetic disorder due to the accumulation of mutations, 
tumor genome sequencing has been used to guide treatment in oncology, as well as to 
develop new therapeutic anti-cancer targets [45]. It is known, that cancer that look 
identical through the microscope may have very different underlying genetic changes and 
may respond differently to specific drugs. By identifying the mutational profile, or 
signatures, specific for a certain type of cancer, it would be possible to classify individual 
groups of patients who may have better responses to an specific treatment, and rule out 
patients that do not belong to such group, avoiding the secondary effects of an 
unnecessary therapy.  
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2.2 Related Work.  
We will analyze and compare our research from multiple perspectives since it involves 
work in different areas. We will start reviewing the different tools used for analyzing and 
comparing genomes and specific sequences and later we will do an extensive comparison 
of our research versus others which aimed at studying cancer and the genome 
relationships. 
Numerous methods have been developed for analyzing the repeat structure of genomic 
sequences [46][47][48][49], most of which scan for a specific type of repeat such as short 
sequence repeats, palindromic repeats [50], tandem repeats [51][52][53][54], or highly 
periodic short repeat elements [55][56]. In most cases, such methods are unable to detect 
repeats that do not match a predefined pattern and intra or inter-genomic analyses are 
usually very difficult. Other methods [57][58], however, such as the use of Fourier 
transforms for repeat identification, do not search for a specific repeat pattern but rather 
try to locate occurrences of highly correlated periodic repeats. Nevertheless, this 
approach typically only identifies very strong genome-wide correlations such as those 
due to the triplet nature of the genetic code.  
Among the tools we have in Bioinformatics, we identify the ones that look for sequences 
within another sequence or genome and the ones that look within established patterns 
(motifs). 
 
2.2.1 Fasta [59] 
First fast sequence searching algorithm for comparing a query sequence against a 
database. It is a tool that works for comparative analysis of DNA against DNA searches. 
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One of its limitations is that it can only find one gapped region of similarity and performs 
relatively slow. However, on the positive side, it does not require specially prepared, 
preformatted databases. 
 
2.2.2 Blast [60][61] 
The Basic Local Alignment Search Tool (BLAST) was developed at the National Center 
for Biotechnology Information (NCBI) [62]. It is not normally used for DNA against 
DNA searches without translation because of optimization issues. This tool pre-filters 
repeat and “low complexity” sequence regions and it is capable of finding more than one 
region of gapped similarity. BLAST’s implantation consists of a very fast heuristic and 
parallel algorithm with the restriction of precompiled, specially formatted databases. 
 
2.2.3 RepeatMasker [63][64] 
This program searches DNA sequences for repeats that present gaps between them. 
Sequence comparisons in RepeatMasker are handled by multiple search engines such as 
cross_match [65], ABBlast/WUBlast [66][67], RMBlast [68] and Decypher [69]. 
 
2.2.4 Masker Aid [70] 
When RepeatMasker was created, scientists started to find repeat sequences for large 
genome sequences; however, they also found that it took fairly huge amount of time to 
the tune of hours to get the process completed on the fastest machines with high end 
processors and memory. MaskerAid was henceforth proposed to take the added benefit of 
WU-BLAST along with cross_match programs. As a result, this patch was applied to the 
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RepeatMasker program in a 4 step process. The new proposed algorithm parses the 
outputs of BLAST programs and finds next the best alignments to find the repeats 
quickly. MaskerAid was run on all the existing conditions which cross_match satisfied 
and showed significant reduction in time taken across modes. Also the miss rate of repeat 
sequences was much reduced. The tool was also seen as lesser sensitive to user-
defined/external parameters than RepeatMasker. 
 
2.2.5 Tandem repeat finder [71] 
Scientific studies show that tandem repeats have something special about them and they 
can be connected to important biological consequences observed in living beings. Hence, 
it is very important to find all Tandem repeats in DNA sequence quickly and efficiently 
regardless of the size of the genome sequence. Before the Tandem Repeat Finder 
appeared, the existing algorithms worked fairly well even though they had various 
disparities. Moreover, many had unacceptable worst case running times for large 
sequences. Few considered large and small sequences alike and to predict a pattern took 
unreasonable time for smaller sequences. Others were bounded by the inclusion of 
approximate repeats and due to the concept of substitution by a fixed number, it made 
little sense to apply the same algorithm to small and large sequence at the same time. 
Tandem Repeat Finder takes all these factors into consideration and comes up with a 
solution which comprises of the following features and more: k-tuple matching and no 
size limit of repeats. This solution also finds hidden tandem repeats using a probabilistic 
model and, finally, aligns these repeats to obtain a consensus pattern. To end the process, 
these repeats are clustered together for further analysis. 
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2.2.6 Reputer [72] 
Exact repeat sequences are the ones that appear at least twice or more in the entire 
genome nucleotide sequence. Next, maximal repeats are basically exact repeats extended 
in both directions without loss of mismatch. These can be classified as Forward Repeats 
or Reverse Complement Repeats. A Reverse Complement of sequence AACCTTGG is 
CCAAGGTT. 
Repeats are stored in the suffix tree for finding the pattern efficiently. Storage wise this 
algorithm is far superior to existing ones. In order to enumerate all repeats existing in the 
parsed sequence, a Depth-First search of the entire tree is required. This enlists one by 
one all the repeats with their coordinates and lengths stored in the end nodes. The 
algorithm is highly optimal from space and time considerations and can be further 
optimized for space constraints. 
 
2.2.7 The Vmatch large scale sequence analysis software [73] 
This work uses suffix arrays [74][75] to pre-process genomes, creating indexes which 
allow quick searching of probes. This brings the limitation given by the size of RAM 
memory present in the executing environment. At this time Vmatch in 32 bit computers 
has a limitation of genomes of 400 million bases. 
 
2.2.8 Amadeus [76] 
Amadeus is a software platform for genome-scale identification of known and novel 
motifs (recurring patterns) in DNA sequences, applicable to a wide range of motif 
discovery tasks. Amadeus can be used to identify binding site motifs from Protein 
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Binding Microarray data. A dataset includes its measured binding intensities for each 
probe sequence covering together all possible 10-mers. In a number of competitions  
Amadeus ranked first (tied with one other group) in identifying the binding site motifs of 
66 TF datasets. Running time is a few seconds per dataset. 
 
2.2.9 Allegro [77] 
Allegro is a software tool for simultaneous discovery of cis-regulatory motifs and their 
associated expression profiles. Its inputs are DNA and genome-wide expression profiles. 
Its output is the set of motifs [78] found, and for each motif the set of genes it regulates 
(its transcriptional module). Allegro is highly efficient and can analyze expression 
profiles of thousands of genes, measured across dozens of experimental conditions, along 
with all regulatory sequences in the genome. Allegro has a user-friendly graphical user 
interface. 
 
2.2.10 Our work 
Our work works with mutations in general not necessarily following an exact or 
approximate  match to any known signature. All mutations that we want to predict are 
made at the molecular level, and cover not only one specific gene nor chromosome but 
the whole human genome. 
 
2.2.11 Comparative chart 
Finally a comparative chart of our approach is presented together with other methods 
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mentioned in related work in table 2.3.   We can observe that our framework works on 
any type of sequences just like other applications; however, our work is oriented towards 
the prediction of new mutations over time in the human genome.   
 
Table 2.3. Comparative chart of our work versus other approaches. 
 
 
 
 
2.2.12 Other studies on cancer genomics  
One out of eight deaths is caused by Cancer [79]. A more in-depth understanding of 
cancer is a must in order provide better treatment for patients. Nowadays, genome data 
Program Alignment Mismatch 
Exact 
Match 
Search against Prediction 
Fafsta YES YES YES Any Sequence NO 
BLAST YES YES YES Any Sequence NO 
Repeat 
Masker 
YES YES YES Any Sequence NO 
Masker Aid YES YES YES Any Sequence NO 
Tandem 
Repeat 
Finder 
NO YES YES Any Sequence NO 
Reputer NO NO YES Any sequence NO 
VMATCH NO NO YES Any sequence NO 
Amadeus NO YES YES 
Predetermined 
database 
NO 
Allegro NO YES YES 
Predetermined 
database 
NO 
Our work NO YES YES Any Sequence YES 
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increases exponentially, which leads to more opportunities to learn insights of this 
terrible disease. David von Hansemann and Theodor Boveri examined strange 
chromosomal aberrations of cancer cells by dividing them under a microscope [80]. 
These findings indicated that cancer might be related to abnormalities at the chromosome 
level [81][82]. 
 
The molecular level analysis can be dated back to the 1980s, Reddy et al. [83] first 
associated a single base substitution of G > T of the HRAS gene with the activation of 
that specific oncogene function in T24 human bladder carcinoma cells. That is the first 
study of identifying a certain mutation as being highly correlated to cancer. Currently, a 
generalizable concept of cancer states that malignancies result from accumulated 
mutations in genes that increase the “fitness” of a transformed cell over the cells 
surrounding it. The transformed cells sometimes acquire advantageous mutations which 
enable them to proliferate unlimitedly and sometimes allow them to spread to distant 
sites, leading to metastases. 
Application of Wavelets 
Wavelets transforms have become an integral part of mathematical analysis with an ever 
increasing range of applications, including genomic sequences. Prasad and Iyengar, 1997, 
in a publication titled Wavelet Analysis with Applications to Image Processing [84], 
describe several methods on the application of wavelets as a tool for feature extractions 
and other important methods in interdisciplinary applications. More recently, Meng, 
Chen, Iyengar and others [85], have published a paper on the applications of wavelets for 
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cancer related genome sequences.   
Wavelet Analysis 
In order to conquer cancer, there is a high demand to delve into these sequences and mine 
useful information. From the signal processing point of view, biological sequences such 
as DNA sequence can be viewed as one dimensional signal. Accordingly, signal 
processing approaches can be adopted. The classic approach of Fourier transform suffers 
from the loss of temporal information. It does not give access to the signals’ spectral 
variations during different time intervals. In other words, the time and frequency 
information cannot be seen at the same time, and thus a time-frequency representation of 
the signal is needed. 
Wavelet analysis which is capable of decomposing time series into time-frequency space 
gets increasing amount of attention as a potential tool to study cancer genomic data. 
Figure 2.9 illustrates the general framework of the analysis procedure. 
The origin of the wavelets theory dates back to the Fourier analysis developed by a 
French mathematician, Jean Baptiste Joseph Fourier (1768-1830) [86]. He came up with 
the idea of representing each signal as a weighted sum of cosine and sine functions, i.e., 
Fourier Trigonometric series. Most real-world signals’ characteristics are non-stationary 
signals and vary in both time and space. FT is trying to capture frequency content. The 
calculation for FT is in Equation (1) from [84]. 
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Figure 2.9. Sample procedure of applying wavelet transform in cancer genome analysis. 
The FT defines the global representation of the frequency content of a signal over a total 
period of time. However, it does not represent to the signal’s spectral variations during 
this interval of time. In other words, people cannot view the time and frequency 
information concurrently.  Nevertheless, it would be helpful if both pieces of information 
were available. 
To achieve this, Dennis Gabor proposed the Short-Time Fourier Transform (STFT) to 
study a small fraction of the signal at a time by segmenting the signal using windows
[87]. This obtains the specific contents of each of the analyzed sections separately. The 
segment of signals in each section is assumed stationary.  
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However, an important question is raised, which is how to determine the window size. As 
is shown in experiments, a narrow window results in a poor frequency resolution, 
whereas a wide window leads to poor time resolution. In addition, one cannot determine 
the time intervals where a certain frequency exists. Therefore, the wavelet transform was 
initially proposed as an alternative approach to STFT to overcome the resolution 
problem. All other windows are the dilated, compressed, and shifted versions based on 
the mother wavelet.  
In terms of history, Haar Wavelets family was developed by Alfred Haar in 1909 [88]. 
The simplicity of this wavelet transform gives it broader applications. It is generally used 
to analyze a given signal in terms of functions which are more finite in time than the 
harmonic functions used in the Fourier analysis. In 1980s, Jean Morlet replaced the 
Gabor window used in Short-Time Fourier Transform (STFT) [89] by stretching and 
compressing oscillating windows. Using this technique, he got more reliable and accurate 
results. This approach is later named as the Morlet Wavelets. In 1989, the idea of multi-
resolution was proposed [90]. This idea forms the base theory of versatile wavelets 
families. Based on this concept, the well-known and frequently used Daubechies 
wavelets family was invented [91]. 
To sum up, wavelet analysis techniques have the following advantages over the 
traditional FT [92]: (a) wavelets are capable of analyzing both stationary and non-
stationary signals, while FT gives less information in analyzing non-stationary signals; 
(b) wavelets have a god localization of frequency and time domains while the standard 
FT is only hgandled  in frequency domain; (c) the base functions of wavelets can both be 
scaled and shifted and therefore are more flexible, while the FT can only be scaled; and 
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(d) wavelets have a much wider range of applications than FT. For example,  they could 
be used in non-linear regression and compression. A brief summary of the comparison is 
shown in Table 2.4. 
 
Properties Fourier 
  
Wavelet 
 
Stationary signal Yes Yes 
Non-stationary signal No Yes 
Time domain No Yes 
Frequency domain Yes Yes 
Scale Yes Yes 
Shift No Yes 
 
Table 2.4.  Comparison of Wavelet Analysis and Fourier transform (FT). [85] 
 
Renato Dulbecco raised the point that the complete sequence of the human genome 
would be an essential tool for systematically discovering the genes that cause cancer [93]. 
The recent advance of next-generation sequencing technology makes the whole cell 
genome analysis possible for individual cancer case. In recent years, data about 
epigenome and transcriptome on a genome-wide scale of cancer grow exponentially [94], 
which offers great opportunity to unlock the mystery of cancer. The main streams of 
existing work of applying wavelet analysis in cancer genome research are summarized as 
follows.  
Cancer is caused by mutations, Generally speaking, there are four types of  
common mutations in the cancer genome, which are substitution, insertion or  
deletion (indel), copy number altercations, and translocations. They are  
illustrated in Figure 2.10.  
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Figure 2.10. The four types of mutations. [92] 
 
Wavelet Analysis in Insertion/Deletion Mutations in Cancer Genome 
As described in previous section, cancer  is  caused by different mutations in the cancer 
genome. Recent studies find that the form and rate of mutations depend on  the  context  
of  the  mutation point  [95]. Wavelet analysis finds its application in this scenario since it 
provides a multi-scale analysis on the sequence without pre-defined prioris. Therefore, it 
is suitable for detecting spatial patterns of the sequences around the mutation point 
without any prior knowledge. In a previous study [96], the authors targeted at identifying 
the spatial distributions of seven types of mutation related motifs, such as deletion 
hotspots, DNA pol pause/frameshift hotspots, etc, with respect to insertion/deletion break 
points. The authors first computed the motif frequency to generate the mo- tif frequency 
profile. Because of the computational simplicity, Haar wavelet analysis was applied to 
de- compose the frequency profile. The coefficients’ sec- ond raw moments on a multi-
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scale basis were computed and they were used to measure the size of the difference 
between motifs occurrence patterns in insertion/deletion flanks vs. control regions. Their 
study identified the significant spatial distribution patterns of mutation motifs. The 
identified motifs could be utilized as targets for some cancer medicine. In another study 
presented in [97], the authors collected  1625  spontaneous  base-pair  substitutions  in the  
MutL2  strain  of  Escherichiacoli  and  analyzed the spatial distribution of these 
mutations across the Ecoli  genome.  In  order  to  accommodate the  total number of 
mutations and describe the data clearly, the researchers generated 46 bins, each of which 
contains 100kb nucleotides, starting at the origin of replication. A histogram was 
generated to show the distribution of missense mutations. Next, the Fourth- order  
Daubechies wavelet transforms were  applied since it is able to remove jumpy appearance 
of the Haar averaged signals. The analysis found that these mutations are not distributed 
at random but, instead, fall into a wave-like spatial pattern that is repeated almost exactly 
in a mirror image in the two separately replicated halves of the bacterial chromosome. 
These findings give some insight on different mutations occurred in cancer genome. 
Wavelet Analysis in Copy Number Alterations 
Copy number alterations are a common pattern of structure variations in cancer genome. 
This sort of mutations is one hot research area in cancer genome research nowadays. 
Generally speaking, the main methods of detecting this sort of mutations, fall into two 
categories, which are the microarray-based gene expression analysis approach and the 
next generation sequencing-based approach. There have been studies utilizing wavelet 
analysis in both approaches. In terms of the first approach, the study [98] is an exemplar. 
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In this paper, the expression level values of each gene are on the vertical dimension and 
locations of genes on the chromosome are the on the horizontal dimension. The problem 
of detecting copy number variations was modeled as extracting salient information on the 
transformed curve, such as sharp peaks and drops of the signal under the high noisy 
situation. As mentioned previously, although Fourier transform is helpful in signal 
processing to transform the time series to frequency domain, it loses information 
regarding position of signal changes, which is important information gain from this study. 
Therefore, wavelet transforms which capture information in both the frequency and time 
domains, are suitable for discovering sharp discontinuities on the genome locations. 
Specifically, the signal profile is first decomposed into a family of multi-resolution 
subbands using Haar wavelet. For each subband, p-values are assigned to Haar 
coefficients based on a null-distribution estimated from normal reference samples. 
Following that, significant coefficients are selected by assigning thresholds for false 
discovery rate. The selected coefficients are used to identify copy number alterations. The 
reason to select the Haar wavelet transform is that it is good for analyzing piecewise 
constant copy number signals [99]. Other similar studies following this direction include 
[100] and [101]. 
The  next  generation sequencing-based methods  provide  a novel and effective solution  
for  analyzing the copy number alterations in a relatively high resolution. Nevertheless, it 
suffers from the relatively high noise issue [102]. One benefit that the wavelet analysis 
provides is its capability of decomposing the signal into a spectrum of different 
frequencies, where many high frequency components are corresponding to noise. 
Therefore, one direct application of the wavelet decomposition is to do the noise 
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reduction. In [103], a CNAseg algorithm is proposed to identify copy number alterations 
from the second-generation sequencing data. In this study, the counts of copy number 
along the chromosome coordinates were converted to the discrete signals and an 
undecimated discrete wavelet transform was utilized to smooth the counting data. The 
number of decomposition levels was adapted to the length of the window counts for each 
chromosome. The reconstructed signal then went through the Hidden Markov Model 
(HMM) for segmentation and the Chi-square statistics based segment merging step. 
Experimental results demonstrated that those proposed approaches decrease the number 
of non-copy number alteration induced HMM segments and reduce the unevenness in 
read depth. Such reduction helps improve the performance of the system. The wavelet 
decomposition-based noise reduction is commonly used in studies in this research 
direction, such as in [100] and [102]. 
Wavelet in Machine Learning Research Frame- work of Cancer Genome 
Nowadays, cancer genomics and proteomics data increase faster and faster. Meanwhile, 
more and more machine learning based approaches are applied by researchers for cancer 
genome analysis. We assume here that mathematical models could be built to learn 
patterns and could make predictions for unseen data by mining the patterns from the 
existing data. Firstly, the raw data are to be converted into a related compact and 
meaningful representations for this propose. We usually call this process as feature 
extraction. It could be utilized to extract features from a series because wavelet analysis 
could capture the global and local characteristics of sequence data. My applications used 
wavelet analysis as feature extraction approach. As an example, in [104], researches 
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utilize wavelet analysis to extract features from DNA microarray data in order to extract 
important features for classification. Another example is that Liu et al. [105] proposed a 
framework which utilizes wavelet to extract features from thousands of protein markers 
in survival analysis in the field of colorectal cancer. Daubechies wavelet db7 is utilized 
by Liu to perform the continuous wavelet transform to extract the coefficients from the 
protein marker expression data. These coefficients contain information at different scales 
of the original biomarker signal. Afterwards, they are been used as features for cancer 
classification. 
Cancer is a very terrible disease which caused by mutations and one of the most problem 
human faced in this generation. It is viewed as a genetic disease. In conclusion, a good 
understanding of the mechanism of mutations is mandatory to combating this disease. 
Wavelet analysis has found its application in many areas of cancer genome research, such 
as mutation identifications and cancer bio-marker identifications. It can perform multi-
scale analysis and capture the local and global information of a time series. 
Similar to the Wavelet technique previously discussed, our work also utilizes a machine-
learning approach in the analysis of the cancer genome. Specifically, speaking, our 
objective of using such approach is being able to make predictions of mutations within 
the genome of a patient. 
2.2.13 Clinical perspective 
From the medical point of view, our analysis focuses mainly on cancer, a disease that is 
caused by mutations and affects the genome leading to instability and the generation of 
more mutations. Through numerous studies, scientists have been able to relate certain 
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cancers somatic mutations in different genes in the genome. As a result, classifying 
cancer based on gene expression has provided much insight into the complex landscape 
of multiple interactions between gene networks, as well as into possible treatment 
strategies. Furthermore, the constant appearance of more sophisticated sequencing 
strategies have helped in the advance of the study in cancer genomics. This has allowed 
scientists to interrogate cancer-specific genomic variants and compare them with the 
normal variants in the same patient. Next generation sequencing (NGS) technologies can 
provide genome-wide coverage at a single nucleotide resolution and at reasonable speed 
and cost. By having the unprecedented molecular characterization provided by NGS 
offers the potential for an individualized approach to treatment. These strategies aim to 
provide the definition of relatively characteristic gene expression profiles, or molecular 
signatures that may have prognostic implications for targeted therapies. 
Consequently, in cancer patients, the objective of NGS is to obtain and compare 
information about cancer and normal tissue DNAs.  By analyzing this, scientists can 
develop a catalog of somatic variants that exist in tumor genome but not in the normal 
tissue DNA. The objective of the analysis is to reveal a drug target in the examined 
cancer which facilitates the selection of therapy, and improves the personalized risk 
assessment. As a result, determining the molecular signatures of genes mutated in cancer 
may help to predict the clinical outcome. 
Researchers and clinicians can benefit from being able to predict molecular signatures 
based on the initial events in cancer development in order to, develop therapeutic 
modifications in treating the patients. Nevertheless, predicting such signatures at the time 
of the tumor diagnosis is a major challenge. Numerous research groups have reported 
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lists of predictive genes and reported good predictive performance in terms of prognosis 
and potential for malignancy based on them. However, the gene lists differed widely and 
had only very few genes in common.  
Additionally, those types of prediction were based on computational approaches not 
involving NGS, such as microarray analysis, qPCR,  and others in various types of cancer 
such as colorectal, lung, prostate, breast cancer and others.  
After searching PubMed we found very few articles reporting predictions in cancer gene 
signatures by utilizing the NGS approach [106][107]. Furthermore, these reports have 
dealt with predictions from data obtained at one point in time from paired normal and 
cancer tissues. To the best of our knowledge, there have been no reports on predictions of 
cancer gene signatures during cancer progression in the same individual. 
Thus, the disadvantages of current predictive models in cancer are that they are focused 
on evaluating mutations that anticipate the risk of progression and its clinical impact on 
the length of patient’s survival. They are not intended to predict mutational events at 
molecular level, only to detect and classify existing mutations. Thus, they are not suitable 
for making predictions in terms of the molecular behavior of the cancer genome. 
In our hypothesis, by having the full sequence of the genome from both normal and 
cancer tissue at different points in time, we are able to extract valuable information to 
validate the predictions generated from genome data before relapse time. After an 
exhaustive search of the available scientific resources (PubMed, Google Scholar), we 
could not find reports utilizing such strategies.  
In order to fill this gap, in our study, we proposed to search for studies of cancer patients 
with such identified mutated genes by the use of NGS various points in time. The 
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mutation profile identified earlier in time will serve as the basis for the prediction at later 
in time. Furthermore, in order to evaluate our prediction results, we compared the 
observed mutated locations at the time of relapse with the results of our own predictions.  
 
Our main objective in this study was to test a computational framework utilizing 
published data from a longitudinal study of patients with acute myeloid leukemia (AML) 
whose DNA from both normal as well as cancer tissues were subjected to next generation 
sequencing analysis at various points in time. First of all, we processed the sequencing 
data at the time of cancer discovery. Secondly, we tested our framework by predicting the 
regions of the genome to mutate at the time of relapse. Finally, we compared our results 
with the observed mutated regions, identified by sequencing their genomes at the time of 
relapse and determined that our predictions are in good agreement with the reported data. 
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CHAPTER 3 
 
RESEARCH PROBLEM AND SPECIFIC AIMS 
 
 
In this chapter we motivate the problem to be investigated and present a detailed problem 
statement. Our research focus is in the area of Bioinformatics. In the next section we 
provide the motivation for this research by emphasizing the need for a prediction 
framework for longitudinal DNA mutations within the human genome  and highlighting 
the benefits to be gained from conducting the study. In Section 3.2 we concisely describe 
the problem to be investigated. 
 
3.1 Motivation 
 
Over time, the scientific and industry community have made tremendous efforts on 
developing computational solutions to aid the research in molecular biology. These 
computational solutions focus mainly on String algorithms since the DNA can be 
represented as a sequence of a combination of four characters (ACTG). These characters 
are basically what we call the bases in the DNA. Nevertheless, when these sequences 
suffer from alterations in their structures (changes in one or more bases at different 
locations within the whole sequence), implications in the health of the individual may 
appear.  Many diseases are associated with causing these changes (mutations) within the 
genome of an individual. In our case, we are concerned specifically with cancer. 
 
In achieving this goal, we built a computational framework that will perform in three 
main stages. Firstly, the framework will pre-process the files containing the patient’s data 
for feeding the information needed by the prediction stage. Secondly, given the 
information provided by the previous stage, the framework will perform the prediction of 
the number of mutations to occur as well as the locations where these will happen 
through a statistical analysis. Finally, after the framework finishes with the predictions, 
40 
 
the predicted number of mutations as well as their locations will be presented in more 
than one format to the physicians to provide treatment and/or make further discoveries as 
many predicted locations could occur at areas where no known functionality exists. 
Additionally our framework has been implemented in Java and also utilizes statistical 
libraries and tools for accuracy and performance. Thus, our software follows the Object 
Oriented (OO) paradigm and has been developed on the Eclipse Integrated Software 
Environment (IDE) with the currently latest Java Development Kit (JDK 7).  
 
3.2 Problem definition 
 
These changes or mutations in the genome can cause various disorders in the individual 
depending on their number and locations. As a result, knowing how many mutations will 
occur as well as where they will occur become very important matters. 
 
The effort is divided into the following three sub-problems: 
  
1. Being able to perform statistical analysis on a given patient's genomic data. 
 
2. Making reliable predictions for the mutating behavior of the given sequence. 
 
3. Identifying mutations in regions in the genome that have not been considered 
functionally important or relevant. 
 
In order to target the solution of these problems we target three specific aims. Each of 
these provides a solution to every sub-problem previously respectively. 
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3.3 Specific Aims 
 
3.3.1 Aim # 1: To build a tool for statistical analysis on genomic data sets. 
 
In order to carry out our first contribution, we built a framework which is capable of 
extracting statistical information from the genomic data from a patient. It is very 
important to mention that our framework works with the whole genome data from a 
patient and not just with one chromosome or a couple of them. Thus, given the genomic 
data from a patient, we proceed with an analysis at the chromosome level of the whole 
genome. This analysis involves producing statistical data from the mutations present in 
each chromosome. The input for this first stage is the genomic data from a sick patient 
who already presents mutations in his genome.  
 
The statistical analysis involves building a series of variables based on the actual 
genomic data from the patient that later will be used to perform the predictions. 
 
3.3.2 Aim # 2: To utilize this data set and formulate a prediction model. 
 
Our second goal is our primary contribution as it deals with the prediction itself. Our 
prediction works at two levels. First, we will predict the number of mutations to occur 
within one chromosome and, second, the locations where these mutations will happen. 
For this contribution, our framework will make usage of the data obtained at the 
completion from the previous stage to build a prediction model to determine the number 
of mutations to occur. Later, the framework will use another algorithm (Section 7, Fig. 
7.4) to predict the respective locations for these mutations. 
 
3.3.3 Aim # 3: To facilitate the discovery of new functionalities in areas of the 
genome that had not been previously implicated in cancer. 
 
Finally, our third goal consists on providing information to the physicians and scientists 
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that would lead to the discovery or redefinition of new genes and or functionality of 
certain areas of the genome. This happens because when determining the locations of the 
newly predicted locations, scientists will be able to find out that some of the areas in the 
genome where these mutations are predicted to appear do not belong to any known gene 
or known functionality but that they still have repercussions on the patient’s health and, 
as a result, it can be the case that a new gene can be identified or redefined (e.g. the range 
of the gene should be extended) or that perhaps a new functionality from this area has 
been discovered. This information can be provided to the experts in the area of genetics 
since they can perform further analysis in the laboratory to determine what is there or 
what functionality might be hidden. Additionally, a specialized and personalized 
treatment will be possible to obtain due to the fact that we genomic data used was 
specific to the patient. 
 
The importance of our work resides on being able to predict mutations in a patient’s 
genome ahead of time in order to provide information that will potentially assist 
physicians on the selection of personalized therapies they can give and/or the 
development of new specialized drugs.  
 
This prediction is done at the gene and chromosome levels. It provides physicians with 
information to make a reliable estimation of the effects of a mutation. Moreover, it may 
lead to the discovery of unknown functionality within the human genome 
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3.4 Significance and impact of our work 
 
Cancer progression is a complex, multistep process, leading to genomic instability and 
loss of growth control. Scientists are trying to identify the so-called driver mutations and 
differentiate them from the “passenger” mutations that passively follow the driver 
mutations. Without knowledge of the biological functions of the genes this process is 
very difficult to accomplish. Furthermore, a great deal of genes has no known function, 
which make it almost impossible to analyze by this approach.  
 
Based on the mutational profile of the cancer cells before relapse time, we utilized the 
framework to make predictions of new mutations at a later time. The most interesting 
aspect of this work is the possibility of comparing the predictions with real experimental 
data obtained from the same patients at the time of cancer relapse. Those comparisons 
allowed us to generate accuracy values (between 80% and 92% accuracy) which are 
remarkable. To the best of our knowledge, there are no reported studies directed toward 
the prediction of changes at molecular level. Numerous studies dealing with predictions 
based on the mutational signatures in cancer cells are limited to the predictions in clinical 
outcomes, rather than in the changes at the genome level in the cells of a patient.  
 
One of the contributions of our research is the possibility of validating the predicted 
mutational profile with the experimental data. This situation has been possible as a result 
of the revolutionary advances in genome sequencing and data analysis. The second 
contribution of our research is the purely computational approach to make predictions 
with no need to include data on the underlying biological processes. This is by far the 
most exciting possibility. Scientist working on the molecular biology and genetics of 
cancer experience great difficulty in characterizing the function of an unknown gene 
which is the first step toward its identification whether is critical or not in cancer 
progression.  
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By utilizing our approach, there are no requirements to ascertain the function of genes for 
the prediction to take place. The third contribution is about providing a target for cancer 
therapy. As a result of the prediction, scientist will obtain putative target genes to 
identify, characterize, and possibly utilize as targets of pharmacological agents for cancer 
treatment.  
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CHAPTER 4 
DATA MINING AND STATISTICAL ANALYSIS 
 
4.1 Background 
Our framework is implemented in Java and uses internal and external libraries. The 
external library we employed for the statistical analysis and processing of our data is 
Weka.  
After our framework processes the input genomic data and obtains the initial statistical 
information for the DNA mutations for the patients at the chromosome level (explained 
in further detail in Chapter 6), Weka is employed for creating a model at the chromosome 
level. This external library builds a model to predict the number of mutations to occur per 
chromosome. 
We chose Weka since it is one of the most widely adopted tools in academia for the 
purposes of machine-learning and statistical analysis. 
 
4.2 Weka [108] 
Weka is acronym name that means Waikato Environment for Knowledge Analysis. It is a 
software library and tool that consists of  various machine-learning algorithms written in 
Java.. Weka complies under the GNU General Public License. Weka provides features 
for data mining targeting classification, data preprocessing , clustering, regression, , 
among others. Essentially, the purpose is to have an application that can be trained for 
machine learning capabilities and obtain meaningful information through trends and 
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patterns. Weka is open source and is written in Java. Consequently, it is cross-platform. 
Weka brings a user-friendly and graphical interface that allows for quick set up and 
operation as well as a programmable API. The data we use to feed Weka is given in the 
form of as a flat file or relation, meaning that every data object has to be described by a 
specific number of attributes of a specific type which can be either alpha-numeric or 
numeric values. In essence, this tool allows users to discover  information that is 
normally hidden from database and files in general. Classification is the core of Weka's 
functionality. All of the newest and older machine-learning (ML) algorithms follow an 
object-oriented (OO) Java class hierarchy. Additionally, regression, association rules and 
clustering algorithms are also part of Weka's implementation.  
All the following definitions and examples regarding Weka were obtained from [109]. 
 
Weka basic concepts 
For a better understanding of Weka, certain concepts are to be clarified. 
 
4.2.1 Dataset 
A dataset is an essential concept for machine-learning and it can easily be thought of as a 
two-dimensional array or table. A dataset represents a collection of samples which are of 
class Instance. Attributes from an instance are nominal, numeric or strings. Externally 
speaking, the representation of an Instance class is a file in ARFF format. This file 
contains a header with the attribute types and the data as comma-separated list. 
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4.2.2 Classifier 
Every learning algorithm is a sub-class from the abstract Classifier [110]. The 
requirements for a classifier are: a routine for the classifier model from a training dataset 
and another one for evaluating the generated model.  
 
4.2.3 Weka from Java – API 
WEKA functionality can be called from Java sub-routines by the utilization of its API. It 
runs similar to when calling classifiers with -p 0. Nevertheless, unlike Evaluation, it 
produces the full class probability for any classifier. The java API comes in the form of a 
jar file and can be incorporated into any Java project. The functionality can be invoked at 
any time from any pat from the source code of the program. 
 
4.3 Statistical Analysis 
Numerous statistical analysis have been developed through time in order to model 
complex systems or problems [111][112][113][114]. Iyengar and Rao present a great 
analysis on statistical techniques for modeling complex systems [115]. Here they present 
single and multi-response models that are representative of modeling complex systems. 
Their work starts with various concepts related to linear and nonlinear models and then 
examines four representative techniques of model discrimination that utilize non-intrinsic 
and intrinsic parameters, Bayesian methods, and likelihood discrimination. Additionally, 
the authors also evaluate multi-response models which deal with issues from design of 
experiments for parameter estimation and model discrimination. 
Similarly, as mentioned in the previous section, Weka allows for a selection of a variety 
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of models and machine-learning algorithms. Depending on the size and type data we are 
dealing with, one model will adjust better for prediction analysis than another. Thus, in 
our scenario, linear regression was the model that best fit to our predicting and gave more 
accurate results. However, we are open to the inclusion of other models in the future as 
our data size increases and therefore, the usage of the Weka API in our framework in 
order to achieve future adaptability and scalability. 
 
Linear Regression 
The approach of Regression is applied in statistics to model a relationship between one 
dependent variable and a set of one or more explanatory/independent variables [116]. If 
the explanatory variable were just one, then we call it simple linear regression. In any 
other case, it is called multiple linear regression.  
Linear regression is used mainly in two types of applications: 
1. For prediction. Here we build a predictive model for a given set of observed data. 
With this model, we can perform predictions for a future point in time based on a 
set of previous points in time (training data). 
2. For measuring the intensity of the relationship among the dependent variable and 
the explanatory variables. This allows to know which explanatory variables have 
higher impact on the value of the dependent one and which ones don't. 
The least squares approach is the most widely used method to calculate the coefficients 
from a linear regression model. 
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The model has the following form: 
 
where all betas are the coefficients and all the Xi are the features. Finally, epsilon is the 
error or noise to adjust the model. 
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CHAPTER 5 
MODELING CANCER RELATED GENOME SEQUENCES OF PATIENT DATA 
 
This chapter is directly related to our second contribution which is the creation of a 
model to predict the DNA mutations. Here, we discuss the reasoning behind the selection 
of our model, that is, the linear regression model. 
 
5.1 Introduction 
The importance of modeling of cancer related genomic data has generated much attention 
from researchers from various interests, primarily from pharmaceutical design 
companies. The most common means of finding correlation of genomic data is by 
structuring a statistical model for the system through which we can predict, control and 
optimize the variables. A detailed exposition of statistical techniques in modeling of 
complex systems (single and multi-response models) can be seen in a well-known 
publication [115]. This chapter examines a representative technique for designing 
experiments and providing a mathematical structure for the analysis of the data that we 
have collected in our study.  
 
5.2 Statistical analysis for our model 
In this study, the prediction values are numerical. From the perspective of data mining, 
this problem can be modeled as a regression problem. In our research problem, one 
challenge is that the training data instances are limited since it is costly to gain patient 
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data.  As is known in data mining field, fitting a high order model would require learning 
more parameters, which needs a large number of samples.  
If we tried to use a higher order model such as non-linear models, then we would be 
facing the problem of over fitting. The results in such case would be totally off as we 
could observe when switching Weka to other algorithms. When using a higher order 
model, the number of instances has to be considerably larger compared to the number of 
features in the model; however, in our case, the number of features and the number of 
instances have a ratio of almost 1 to 1 which obviously would bring the problem of over 
fitting. 
Given this observation, the linear regression model which fits a linear equation to features 
and the target variable is utilized. Specifically, three selected numerical features 
(explained in Section 7.3) are normalized and fit to the linear regression model. The 
general form of the model is represented as Y a= + bX , where Y is the predicted value 
and X  is the normalized feature vector. b  is the weights and a is the error term. In 
addition, our prediction task has a temporal dimension. Assuming there are N observation 
time points, which are T1,  T2, …, TN, , suppose we want to predict the mutation number at 
time point TN  utilizing the features from T1  to TN-1.  A natural assumption is that the 
mutation number is highly correlated with features at time point which are close to TN.  
However, it is very difficult to measure this numerically. The linear regression model 
provides a nice way of quantifying the contribution of each feature. The significance of 
the features are represented by the corresponding weights trained in the model under the 
condition that all features are normalized. For example, if the learned parameter for 
feature F1 is 100, and the other parameter for feature F2  is 0.01. We can conclude that 
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F1 is more important. This property can give us more insight in our study as we want to 
know which features are important.  
 
5.3 Mechanisms and Models 
In order to fit the linear regression model, the mathematical approach of learning the 
parameters needs to be defined. In this dissertation, we model the learning of parameters 
as an optimization problem, in which the object function is the mean square error. 
Formally, assume for the predicted value iy  for data instance i (1 ≤i≤M), M  is the total  
number of chromosomes in one patient. Three features are represented using 1
iF , 2
iF , 
and 3
iF . Let the corresponding parameters be β0 , β1,  β2,  β3 . The cost function, which 
corresponds to the half mean square error can be summarized as follows: 
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In order to minimize this function, the gradient descent algorithm can be utilized. The 
partial derivative of the function with respect to β0 , β1,  β2,  β3  are as follows: 
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In each iteration of updating the parameters, β0 , β1,  β2,  β3  are updated as follows: 
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Using the matrix annotation, assuming matrix F, which is shown as follows: 
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And the parameter β and the response vector y, which is defined as follows: 
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So the model could be written as:  
' =y Fβ  
 
The cost function can be written as: (M  is the total  number of chromosomes in one 
patient): 
1 ( ') ( ')TJ
M
= − −y y y y  
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If we minimize this function, we can get the solution for  β  as:  
1( ) ( )T T−= F F F yβ  
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CHAPTER 6 
MATERIALS AND METHODS 
 
We searched for reports that included whole-genome sequencing strategies in their 
methodology. In order to select suitable studies, we defined a number of requirements, 
namely studies which were longitudinal, had reported findings on more than one patient, 
had data which was completely anonymous and publicly available and downloadable in a 
suitable format. The studies we reviewed had enrolled several patients. The reported 
results were publicly available and included multiple data on patient’s genome during 
diagnosis from both healthy and cancer tissues, as well as whole-genome sequencing data 
from affected tissues during disease relapse. Although genome-wide sequencing 
strategies have been available for more than a decade, there are still a relatively small 
number of published studies where patients’ genome was sequenced after relapse. Most 
of the published scientific literature on whole-genome sequencing encompasses data 
comparing the genome changes at nucleotide level from both healthy and affected tissues 
at one point in time most likely when diagnostic procedures are carried out. As the 
technologies become less expensive and more widely available, various research groups 
have started to carry out longitudinal studies where patients’ genome is sequenced several 
times during the disease’s progression.  
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6.1 Framework 
We built a framework which is capable of extracting statistical information from the 
patient’s genomic data. Our framework works with the whole patient's genomic data from 
one patient and not with just one chromosome. Thus, given the genomic data from a 
patient, we proceed with an analysis at the chromosome level of the whole genome. This 
analysis involves producing statistical data from the mutations present in each 
chromosome. The input for this first stage is the longitudinal sequencing data from a 
patient’s tumor where mutations have been identified and characterized.  
All data to be used needs to be normalized into a standard format as will be presented in 
the next sections. As more data is obtained from the patients, more training will be 
provided for our model. Figure 6.1 below shows this in a graphical manner. 
 
6.2 Patient data 
Whole genome sequencing data from eight patients with acute myeloid leukemia (AML) 
served as a basis to test our framework. The data was available as supplementary material 
to an article published in 2012 by Li Ding et al. in the journal Nature [13]. These patients 
were from five different French-American-British hematologic subtypes, with elapsed 
times of 235 to 961 days between samples (see Table 6.1 for each individual’s 
information). The goal of the study was to investigate the mutational profiles of primary 
tumors and determine whether the clonal evolution of mutations contributes to relapse. 
We provided our framework with longitudinal data for the mutational profiles observed 
in the genomes of patients in order to generate a prediction of nucleotide changes 
(mutations), followed by a comparison of those predictions with the actual mutations 
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detected by whole-genome sequencing of the tumors after relapse, thus allowing us to 
measure accuracy and significance of our approach. 
 
 
Figure 6.1. Dependency flow graph for our prediction framework. 
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Due to different sources of data, and in order to work in a consistent manner, we decided 
to format all data in a specific manner as explained below. For sequencing data 
comparisons and evaluations, we aligned the coordinates of input data as well as the 
coordinates of the resulting predictions to NCBI build 36.3 of human genome assembly.  
Information corresponding to each patient was labeled with the letters ‘A’ through ‘H’. 
Data was downloaded as plain text files. Files, called “shared.txt”, contain the locations 
of mutations identified. Files, called “relapse.txt”, contain the locations of mutations 
reported after relapse.  
 
 
 
 
 
 
 
 
 
 
Table 6.1. Patient designation, gender and age. 
 
 
 
 
UPN 933124 Caucasian female late 50s 
UPN 400220 Caucasian female, 34 year old 
UPN 426980 Caucasian male, 69 year old 
UPN 452198 Caucasian male, 55 year old 
UPN 573988 Caucasian female, 67 year old 
UPN 869586 Caucasian male, 23 year old 
UPN 758168 Caucasian female, 25 year old 
UPN 804168 Caucasian male, 53 year old 
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In Figure 6.2, we show a partial view of the files previously mentioned in order to get an 
understanding of the way we have been working with them. 
In order to map the coordinates of mutations to genes or genetic regions, we downloaded 
a file from NCBI build 36.3 of the human genome assembly that contains gene names 
and location ranges per chromosome in a text format and saved it as geneMap.txt. The 
file is used to determine which genes will be involved depending on the locations of the 
predicted mutations. 
 
Limitations of Data 
Obtaining patients data is extremely difficult especially because of HIPAA limitations. In 
our case, we even required data in a longitudinal manner which increased made it even 
harder. We attended several seminars given by the University of Miami at Jackson's 
Hospital. During these seminars, medical doctors and other scientists presented their 
work on cancer research.  
Throughout these events we kept asking them for possible sources of these data but their 
answer was always that the data in a longitudinal manner was very hard to get. 
Nevertheless, on May 17th, 2013, Dr. James Downing [117], gave a talk titled "The 
pediatric cancer genome project". Dr. Downing is the Scientific Director for Saint Jude 
Children's Research Hospital and his talk covered cancer research that was being done by 
analyzing tumor tissue genomes. After his talk, I asked Dr. Downing for possible sources 
of longitudinal data based on these genomes, and he suggested me to look for patients 
with leukemia since it is in this type of disease where most studies had been done in this 
manner.  
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He indicated it would still be hard to access the data but that it was the best route to take. 
Following his advice, we continued our research and found the article previously 
mentioned were the data was finally available. 
Simulating data was never an option, since in the medical domain this practice is strictly 
forbidden since the conclusions derived from here could be misleading and as a result 
lead to serious medical conclusions. 
When we discussed later our work with a domain expert from the UT Southwestern 
Medical Center, he indicated that our data was very significant since even high quality 
journals published in top journals use les or comparable amount of data. More on this can 
be observed in the conclusion of this dissertation. 
Our studies are based in the molecular level, as a result, the demographics of the data 
(e.g. separation by genders) does not apply. Furthermore, if we were to split the 
demographic aspects such as genders or ages, it would make our data samples even 
smaller since we would require grouping. Finally these demographic aspects are nominal 
features and cannot be fit into a regression model directly. 
Figure 6.2 shows the format to be used for the geneMap.txt file previously mentioned. 
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                   Arelapse.txt 
 
 
Ashared.txt   
Figure 6.2. Sample data files for patient UPN 933124. 
 
 
 
 
 
 
 
 
Figure 6.3. Overview of geneMap.txt. 
 
6.3 Variables to consider 
Having identified mutations and their locations, our framework will analyze how spaced 
these mutations are from each other within each chromosome. After obtaining a vector of 
distances between one mutation and the next, our framework computes statistical analysis 
Chr Location 
1 108346944 
1 147392656 
1 230352346 
2 25310746 
2 77165972 
2 140418446 
3 182087434 
3 191103363 
3 192532267 
3 196997137 
4 7394775 
4 72616906 
4 119477364 
…. 
22      26004684 
X      25476033 
X    105826475 
Chr Location 
1 107357719 
1 179307551 
1 218018901 
1 224145610 
2 184186967 
2 213886052 
3 21310708 
3 43135962 
3 135449546 
…. 
22       26004684 
X       25476033 
X    105826475 
chromosome chr_start chr_stop feature_name 
1  815  19919  LOC653635 
1  42215  43358  OR4G4P 
1  52778  53847  OR4G11P 
1  58954  59871  OR4F5 
1  77385  80096  LOC100132632 
….. 
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such as the mean and standard deviation of these distances to identify how these 
mutations behave. For example, if the standard deviation is very small compared to the 
mean, this signifies that mutations occur with a similar distance from one another. If that 
is not the case, then we can see that some mutations are located very much far apart from 
each other while others are much closer. Thus, the ratio between the mean and the 
standard deviation (RatioStdMean) of the distances is a critical variable to consider by 
our framework. A second statistical variable computed by the framework is also the ratio 
of how many mutations occur within one chromosome when compared to the total 
number of mutations in the whole genome for a given patient (RatioGivenChr). A third 
variable, we called GenRatioPerChr, is a standard variable that has also been computed 
for all experiments. This variable corresponds to the ratio of the chromosome size in 
nucleotides to the length of the whole human genome assembly also in nucleotides. This 
is a standard value as it has been obtained from the reference human genome assembly 
data and it is not specific to a particular patient. Due to the fact that chromosomes are of 
different sizes, there is a possibility of finding more mutation in larger chromosomes than 
in shorter ones. 
 
6.4 Prediction model 
The next step in the framework is about prediction.  Our prediction works at two levels. 
First, we will predict the number of mutations to occur within one chromosome, and then 
the locations where these mutations will happen. For this contribution, our framework 
will make usage of the statistical data obtained at the completion of previous stage to 
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build a prediction model to determine the number of mutations likely to occur. This 
prediction model is obtained by utilizing Weka[118] as explained in chapter 4. 
Weka uses an ARFF file (Attribute Relationship File Format) as an input, and then by 
processing this file, creates the models according to the content of the data and variables 
involved. The weka ARFF file will have the format indicated in Figure 6.4. 
 
@RELATION ChromosomeModelling6 
@ATTRIBUTE RatioStdMean NUMERIC 
@ATTRIBUTE RatioGivenChr NUMERIC 
@ATTRIBUTE GenRatioPerChr NUMERIC 
@ATTRIBUTE NumMutations NUMERIC 
 
@DATA 
….. 
Figure 6.4. Weka input file. 
 
For our purposes, the framework creates an ARFF file per chromosome containing the 
data for it along with the associated computed variables previously mentioned.  
                                                     
Since the prediction model works at the chromosome level, there will be 24 files 
corresponding to 22 somatic chromosomes (1 through 22), and one “X” as well as one 
“Y” chromosome.  
We decided to build a model per chromosome instead of just one model for the whole 
genome. We carried out a preliminary analysis in which we tried to build a model for the 
whole genome, but the results were inconclusive. In addition, existing public data is 
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available in a per chromosome basis. Furthermore, a generic model did not fit well for all 
scenarios due to both the intrinsic varying nature and behavior of each chromosome.  
 
For a given chromosome ‘i’ (1-22, and X as well as Y), our model is of the form: 
iy  = 𝛽𝛽1 * 1
iF + 𝛽𝛽2 * 2
iF + 𝛽𝛽3 * 3
iF + 𝛽𝛽0 
iy  represents the number of mutations we want to predict and 1
iF , 2
iF , and 
3
iF represent the RatioStdMean, RatioGivenChr and GenRatioPerChr respectively. 
Finally, 𝛽𝛽1, 𝛽𝛽2 and 𝛽𝛽3 are the coefficients of the model and 𝛽𝛽0 is the error. Their values 
are provided by Weka. 
These models are obtained by Weka as a String expression and then we parse it and 
execute each model by inserting the variables of each chromosome for each patient to 
predict the number of mutations to occur at relapse time. 
After generating a model per chromosome, we fit the information obtained from Weka 
back into the framework. The framework takes this model to execute the prediction of the 
number of mutations to occur for each chromosome. Once all predicted number of 
mutations have been computed for each chromosome, the framework takes each 
individual chromosome and executes the predictions of the locations of the mutations. At 
this point, since we know the predicted number ‘n’ of mutations likely to occur at each 
chromosome, we perform the algorithm shown in Figure 6.5. 
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Figure 6.5 Algorithm for finding mutations locations. 
 
We deal with data from mutations in each chromosome at different points in time. In our 
algorithm, for instance, we utilize existent longitudinal data on mutations during 
diagnosis and/or treatment to generate a prediction of mutations at a later relapse time. 
Thus, each location 'l' represents the location of an existent mutation before relapse time. 
Next, our algorithm checks whether the distance between mutations is greater than the 
average distance (meanDist), and if that is the case, a mutation will happen within this 
distance at approximate position of the location 'l' + meanDist. Having identified a 
predicted location for a mutation, we proceed to determine whether it belongs to either an 
annotated gene or an intergenic region.  
Due to the fact that we have the actual number of mutations for all chromosomes, as well 
as their individual locations identified at relapse time, we are able to compare our 
predicted results with the experimental data. The results of these comparisons serve as 
our main criteria to estimate the accuracy of the predictions made by the framework. 
 
For i=1 to ‘n’ 
{    for (each existingLocation ‘l’ in chromosome ‘c’) 
 if distance from ‘l’ to ‘l+1’ is greater than meanDist 
 { predict finding here at location ‘l’+meanDist; 
  findAssociatedGene; 
 } 
} 
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CHAPTER 7 
RESULTS 
 
7.1 Prediction of number of mutations per chromosome. 
In order to present, as well as to discuss the results, we selected the data from one of the 
patients as representative of all (UPN 933124, see Table 7.1 for information on the 
patient). Data on other patients and their respective predictions are available on the 
Appendices section. Table 7.1 presents the results for the predictions made by our 
framework with regards to the number of mutations likely to occur for this given patient. 
The first column indicates the chromosome analyzed, and the second column indicates 
the number of mutations observed at the time of relapse (actual number of mutations 
observed). The third column indicates the predicted number of mutations. 
As we can distinguish from Table 7.1, the predicted number of mutations is very close to 
the observed number of mutations that occurred at the time of relapse in all 
chromosomes. In order to calculate the accuracy of the prediction, we consider the 
number of observed mutations versus the number of predicted mutations.  We obtained a 
percent value of the ratio of predicted number of mutations to the total number of 
observed mutations: 83% (35/42). 
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Chromosome Observed Mutations 
Predicted 
Mutations 
1 4 3 
2 2 2 
3 3 2 
4 1 1 
5 2 2 
6 2 2 
7 3 2 
8 5 4 
9 2 2 
11 3 2 
12 3 2 
13 2 2 
14 2 2 
16 3 2 
17 1 1 
20 2 2 
21 1 1 
X 1 1 
Total 42 35 
Accuracy 83% 
 
Table 7.1. Number of mutations per chromosome in patient UPN 933124. 
 
 
7.1.1 Significance of our experimental data 
The following figures show the error distribution of different patients for the predicted 
number of mutations at the chromosome level.  The x-axis is the predicted value minus 
ground truth. The y-axis is the counts. It can be seen that the proposed approach gives 
underestimation of number of mutations on each chromosome of each patient.  
In addition, it also can be observed that our miss-predictions focus on negative one, 
which indicates that the proposed framework is very promising.  
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Figure 7.1 Histogram of absolute error for patient A. 
 
 
Figure 7.2 Histogram of absolute error for patient B. 
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Figure 7.3 Histogram of absolute error for patient C. 
 
 
 
Figure 7.4 Histogram of absolute error for patient D. 
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Figure 7.5 Histogram of absolute error for patient E. 
 
 
 
Figure 7.6 Histogram of absolute error for patient F. 
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Figure 7.7 Histogram of absolute error for patient G. 
 
 
  
Figure 7.8 Histogram of absolute error for patient H. 
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The following figures show the histogram of relative errors. The relative error is defined 
as the error divided by ground truth number.  
 
Figure 7.9 Histogram of relative error for patient A. 
 
 
 
Figure 7.10 Histogram of relative error for patient B. 
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Figure 7.11 Histogram of relative error for patient C. 
 
 
 
Figure 7.12 Histogram of relative error for patient D. 
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Figure 7.13 Histogram of relative error for patient E. 
 
 
 
Figure 7.14 Histogram of relative error for patient F. 
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Figure 7.15 Histogram of relative error for patient G. 
 
 
 
 
 Figure 7.16 Histogram of relative error for patient H. 
 
 
 
 
 
 
77 
 
After a thorough review of our experimental data on the error distribution, we have the 
following results:  
Observation (1): The x-axis is predicted value minus ground truth. The y-axis is the 
counts. It can be seen that the proposed approach gives underestimation of number of 
mutations on each chromosome of each patient. 
Observation (2): It also can be observed that our mis-predictions focuses on negative one, 
which indicates that the proposed computational framework is very promising. 
 
7.1.2 Analysis of performance measures to evaluate the success of our prediction 
The state of the art evaluation criteria for classification models include accuracy, 
sensitivity, specificity, precision, true positive value, and true negative values. These 
metrics are suitable for binary classification problems; however, in our case our research 
problem is a regression problem and, as a result, the previously mentioned criteria cannot 
be applied. Consequently, our analysis for accuracy was different as can be observed in 
the paragraphs below. Detailed statistical analysis of the errors is also provided in Section 
7.1.3. 
We obtained performance measures to evaluate the success of our prediction. For this, we 
defined p1, p2, p3, …, pn as the numeric value of the prediction at the ith instance and we 
define a1, a2, a3,…, an as the actual values at the ith instance. 
The correlation coefficient measures the statistical correlation between a’s and p’s. The 
closer we get to 1 for this value, the better correlated results.  
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Correlation Coefficient = SPA/  where SPA =  
   SP =      and    SA =  
We obtained the mean absolute error which represents the average of the individual 
errors without considering their signs.  
Mean Absolute Error =  
The root mean squared error (most widely used measure). It represents the square root of 
the mean squared error and presents the same dimensions as the predicted value itself. 
Root mean squared error =  
“Simple predictor” is the average of all actual values given by the training data. 
The relative absolute error computes the total absolute error with the same kind of 
normalization. Relative errors are normalized by the error of the simple predictor that 
predicts average values. 
Relative absolute error =  
Finally, the relative squared error represents the scenario where a simple predictor had 
been used.  It is given by total squared error normalized by dividing it by the total 
squared error of the default predictor. 
Relative squared error =  
Finally, all these values are shown in table 7.2 for Patient A.  The respective tables for 
other patients can be found at the Appendices. 
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Table 7.2. Table for performance measures for our prediction model. 
7.1.3 Significance, stability and statistical analysis of model  
In this study, we achieved promising results.  The correlation coefficient, which indicates 
the degree of matching of the proposed framework with real data, is 0.9816  0.009 with 
95% confidence interval. For mean absolute error, we achieved 0.2958 0.087 with 95% 
confidence interval. 
Here we also provide a statistical analysis for all errors across all chromosomes for 
Chromosome Correlation coefficient 
Mean 
absolute 
error 
Root 
mean 
squared 
error 
Relative 
absolute 
error 
Root  
relative 
squared  
error 
1 0.9412 0.6797 0.9251 27.19% 33.78% 
2 0.9999 0.015 0.0181 1.20% 1.22% 
3 0.9994 0.1137 0.1144 3.79% 3.41% 
4 0.9769 0.4618 0.6322 18.47% 21.37% 
5 0.9475 0.6512 0.8757 26.05% 31.98% 
6 0.9998 0.0702 0.0752 2.16% 2.15% 
7 0.9826 0.2975 0.3562 18.31% 18.55% 
8 0.9972 0.1895 0.2338 6.89% 7.51% 
9 0.9403 0.5651 0.7798 28.26% 34.03% 
10 0.9896 0.5765 0.5954 15.37% 14.36% 
11 0.9565 0.4473 0.5969 25.56% 29.17% 
12 0.9946 0.2674 0.3315 8.91% 10.36% 
13 0.9999 0.0314 0.0314 2.09% 1.48% 
14 1 0.0014 0.0016 0.16% 0.15% 
15 0.9995 0.122 0.1225 3.49% 3.22% 
16 0.9609 0.2272 0.3094 22.72% 27.68% 
17 0.9987 0.155 0.1554 5.64% 5.13% 
18 0.9914 0.3529 0.3854 12.83% 13.08% 
19 0.9885 0.3556 0.3766 15.80% 15.14% 
20 0.9702 0.4256 0.5547 21.28% 24.21% 
21 0.9959 0.3202 0.376 8.54% 9.07% 
22 0.9786 0.4876 0.5916 19.50% 20.60% 
X 0.9922 0.2044 0.2841 10.90% 12.47% 
Y 0.9992 0.082 0.1047 3.64% 3.91%
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Patient A. The specific algorithm is given as follows. Because the data collected are 
limited in our case and the population standard deviation is unknown, we use the 
Student’s t-distribution to estimate the confidence interval. For one variable a such as the 
correlation coefficient, n is the number of observations (n=24 in our case). The algorithm 
to compute the confidence interval cf  is as follows.   
ALGORITHM 
Begin 
Step 1: Compute the average value of  a, which is   ; 
Step 2: Compute the standard deviation of  a, which is s; 
Step 3: Set a confidence interval, here we used 95%, which is a golden standard in  
        statistics community. 
Step 4: Compute a T_multiplier, which is the inverse of  Students’ t cumulative    
         distribution function using the confidence interval and the freedom of   
         n-1  
Step 5: Compute a cf  value 
cf  = T_multiplier * s/ n  
Step 6: The confidence interval is [ -cf, +cf] 
End 
The table of the statistics of the first patient is in the below table. As mentioned earlier 
and as it can be observed in Table 7.3, for patient A, we have correlation coefficient as 
0.9834 0.0084 with 95% confidence interval. Additionally, for mean absolute error, we 
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achieved 0.2958 0.087 with 95% confidence interval. Tables 7.3 through 7.10 show 
these measures as well for all other patients. Finally, table 7.11 shows the statistical
analysis for all patients. 
 
mean std cf lower bound upper bound 
Correlation coefficient 0.9834 0.0200 0.0084 0.9749 0.9918 
Mean absolute error 0.2958 0.2061 0.0870 0.2088 0.3829 
Root mean squared error 0.3678 0.2736 0.1155 0.2523 0.4834 
Relative absolute error 0.1286 0.0927 0.0391 0.0895 0.1678 
Root relative squared error 0.1433 0.1123 0.0474 0.0959 0.1907 
Table 7.3. Statistical analysis of errors for patient A. 
 
mean std cf lower bound upper bound 
Correlation coefficient 0.9807 0.0193 0.0081 0.9726 0.9888 
Mean absolute error 0.3000 0.2065 0.0872 0.2128 0.3872
Root mean squared error 0.3730 0.2731 0.1153 0.2577 0.4884 
Relative absolute error 0.1336 0.0922 0.0390 0.0947 0.1726 
Root relative squared error 0.1484 0.1126 0.0475 0.1009 0.1960 
Table 7.4. Statistical analysis of errors for patient B. 
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       mean std cf lower bound upper bound 
Correlation coefficient 0.9821 0.0178 0.0075 0.9746 0.9897 
Mean absolute error 0.3009 0.2056 0.0868 0.2141 0.3877 
Root mean squared error 0.3739 0.2737 0.1156 0.2583 0.4895 
Relative absolute error 0.1329 0.0934 0.0394 0.0935 0.1724 
Root relative squared error 0.1477 0.1123 0.0474 0.1003 0.1951 
 
Table 7.5. Statistical analysis of errors for patient C. 
 
 
 
 
mean std cf lower bound upper bound 
Correlation coefficient 0.9826 0.0168 0.0071 0.9755 0.9897 
Mean absolute error 0.3005 0.2061 0.0870 0.2135 0.3876 
Root mean squared error 0.3732 0.2735 0.1155 0.2578 0.4887 
Relative absolute error 0.1345 0.0923 0.0390 0.0955 0.1735 
Root relative squared error 0.1468 0.1129 0.0477 0.0991 0.1944 
 
Table 7.6. Statistical analysis of errors for patient D. 
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Table 7.7. Statistical analysis of errors for patient E. 
 
 
 
 
 mean std cf lower bound 
upper 
bound 
Correlation coefficient 0.9807 0.0197 0.0083 0.9724 0.9891 
Mean absolute error 0.3012 0.2065 0.0872 0.2140 0.3884 
Root mean squared error 0.3719 0.2740 0.1157 0.2562 0.4876 
Relative absolute error 0.1324 0.0919 0.0388 0.0936 0.1712 
Root relative squared 
error 0.1487 0.1125 0.0475 0.1012 0.1962 
 
Table 7.8. Statistical analysis of errors for patient F. 
 
 
 
 
 
 
 
mean std cf lower bound upper bound 
Correlation coefficient 0.9802 0.0195 0.0082 0.9720 0.9885 
Mean absolute error 0.2997 0.2050 0.0866 0.2132 0.3863 
Root mean squared error 0.3725 0.2749 0.1161 0.2564 0.4886 
Relative absolute error 0.1336 0.0924 0.0390 0.0946 0.1726 
Root relative squared error 0.1476 0.1121 0.0473 0.1003 0.1949 
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Table 7.9 Statistical analysis of errors for patient G. 
 
 
 
 
 
Table 7.10. Statistical analysis of errors for patient H. 
 
 
 
 
mean std cf lower bound upper bound 
Correlation coefficient 0.9814 0.0191 0.0081 0.9734 0.9895 
Mean absolute error 0.2997 0.2062 0.0871 0.2126 0.3868 
Root mean squared error 0.3722 0.2732 0.1154 0.2568 0.4876 
Relative absolute error 0.1337 0.0930 0.0393 0.0944 0.1730 
Root relative squared error 0.1481 0.1120 0.0473 0.1008 0.1954 
 
mean std cf lower bound upper bound 
Correlation coefficient 0.9818 0.0190 0.0080 0.9738 0.9899 
Mean absolute error 0.3019 0.2067 0.0873 0.2146 0.3892 
Root mean squared error 0.3721 0.2733 0.1154 0.2567 0.4875 
Relative absolute error 0.1343 0.0922 0.0389 0.0953 0.1732 
Root relative squared error 0.1479 0.1131 0.0477 0.1001 0.1956 
85
Table 7.11. Statistical analysis of all patients. 
8.1.3.1 Observations
Table 7.11 gives a summary of all eight patients. As indicated in the table, our method is 
relatively stable across different patients. For example, for the eight patients, the 
confidence interval with 95% for the correlation coefficient is 0.9816  0.009. Since the 
eight patients are chosen randomly, these experimental results indicate that our model 
fitting could give around 0.9816 of correlation coefficient measurement. As we know that 
1 indicates the perfect performance. This measurement indicates that our model fits the 
data relatively well.  
Below, we can also see the coefficients obtained for the models at each chromosome per 
patient. We tried to find some patterns among across different chromosomes within the 
same patient and then also tried to find patterns across patients and we could not identify 
any significant patterns.  
 
mean std cf lower bound upper bound 
Correlation coefficient 0.9816 0.0011 0.0009 0.9808 0.9825 
Mean absolute error 0.3000 0.0018 0.0015 0.2984 0.3015 
Root mean squared error 0.3721 0.0018 0.0015 0.3705 0.3736 
Relative absolute error 0.1330 0.0019 0.0016 0.1314 0.1345 
Root relative squared error 0.1473 0.0017 0.0014 0.1459 0.1487 
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For the purpose of showing how the models look like, we show all tables that contain the 
coefficients for the chromosome models for each patient.  
From the model iy  = 𝛽𝛽1 * 1
iF + 𝛽𝛽2 * 2
iF + 𝛽𝛽3 * 3
iF + 𝛽𝛽0,    
𝛽𝛽1, 𝛽𝛽2, and 𝛽𝛽3 are the coefficients for RatioStdMean, RatioGIvenChr and 
ChrToGenomRatio respectively. 𝛽𝛽0 is the error used to adjust the model. 
 
chr 𝛽𝛽1 𝛽𝛽2 𝛽𝛽3 
1 -0.0058 -0.9408 0.00000012 
2 0.0044 -1.1347 -0.00000002 
3 0.0045 4.3818 0.00000015 
4 0.0048 5.3997 0.00000032 
5 -0.0124 -6.074 0.00000017 
6 0.006 4.4676 0.00000009 
7 0.0125 3.0178 0.00000008 
8 0.0084 7.6347 0.00000013 
9 0.0127 -6.1969 -0.00000014 
10 -0.0051 6.0138 -0.00000016 
11 0.0095 2.5017 0.00000027 
12 -0.0061 4.3137 0.00000006 
13 -0.014 -1.5312 0.00000014 
14 0.0051 -0.6632 0.00000018 
15 -0.0102 1.6083 0.00000032 
16 -0.0023 -1.5139 0.00000031 
17 -0.0066 6.0243 -0.00000011 
18 -0.0037 5.1447 0.00000011 
19 -0.014 1.4385 0.00000041 
20 -0.0032 4.1677 0.00000021 
21 0.0061 4.6595 0.00000012 
22 -0.0127 6.8996 0.00000022 
X 0.0068 4.4555 -0.00000053 
Y -0.004 4.9267 0.00000061 
Table 7.12. Coefficients for chromosome models for patient A. 
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chr 𝛽𝛽1 𝛽𝛽2 𝛽𝛽3 
1 -0.0029 -0.7871 -0.00000014 
2 0.0081 -2.3130 0.00000051 
3 0.0108 5.0479 0.00000038 
4 0.0115 5.2580 -0.00000048 
5 -0.0128 -5.3196 0.00000018 
6 0.0042 3.9586 0.00000096 
7 0.0150 2.7207 -0.00000069 
8 0.0083 7.9148 0.00000024 
9 0.0143 -7.0051 0.00000015 
10 0.0009 5.6727 -0.00000033 
11 0.0168 3.8659 -0.00000001 
12 0.0031 3.1030 0.00000029 
13 -0.0228 -2.5005 0.00000088 
14 0.0056 0.5399 0.00000067 
15 -0.0089 2.9604 0.00000046 
16 0.0018 -0.4690 0.00000035 
17 -0.0136 6.4899 -0.00000038 
18 0.0059 6.4388 0.00000000 
19 -0.0180 1.6259 -0.00000027 
20 -0.0051 3.3770 0.00000029 
21 0.0040 5.0753 -0.00000072 
22 -0.0105 6.8326 0.00000019 
X 0.0163 4.8320 0.00000026 
Y 0.0053 4.8783 0.00000132 
Table 7.13. Coefficients for chromosome models for patient B. 
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chr 𝛽𝛽1 𝛽𝛽2 𝛽𝛽3 
1 -0.0072 -0.2514 0.00000071 
2 0.0110 -1.1303 -0.00000086 
3 0.0065 4.7241 0.00000039 
4 0.0077 4.2140 -0.00000051 
5 -0.0145 -7.4037 0.00000050 
6 0.0047 4.9642 -0.00000016 
7 0.0101 2.7127 0.00000057 
8 0.0136 7.7381 0.00000018 
9 0.0122 -5.4405 -0.00000064 
10 -0.0046 7.0865 0.00000008 
11 0.0186 3.1069 -0.00000016 
12 -0.0078 4.4835 0.00000026 
13 -0.0146 -2.2882 0.00000107 
14 0.0047 -0.2342 0.00000085 
15 -0.0132 1.0773 -0.00000027 
16 -0.0039 -0.9811 0.00000116 
17 0.0025 6.0216 -0.00000056 
18 0.0048 6.2068 -0.00000063 
19 -0.0237 0.0305 0.00000055 
20 0.0041 4.9333 -0.00000006 
21 0.0017 5.8057 -0.00000013 
22 -0.0162 6.9951 -0.00000029 
X 0.0050 5.2612 -0.00000036 
Y -0.0020 6.1814 0.00000152 
Table 7.14. Coefficients for chromosome models for patient C. 
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chr 𝛽𝛽1 𝛽𝛽2 𝛽𝛽3 
1 -0.0076 -0.7604 -0.00000076 
2 0.0067 -0.7116 0.00000096 
3 0.0097 5.7364 -0.00000048 
4 0.0139 4.0246 0.00000114 
5 -0.0202 -4.9885 -0.00000002 
6 0.0147 4.4609 -0.00000022 
7 0.0042 2.6177 0.00000107 
8 0.0128 8.7581 0.00000091 
9 0.0192 -5.4743 0.00000070 
10 0.0022 6.3766 0.00000037 
11 0.0194 1.7699 0.00000021 
12 0.0033 3.6173 0.00000102 
13 -0.0120 -2.0102 0.00000015 
14 0.0064 0.7180 0.00000026 
15 -0.0081 2.5469 -0.00000058 
16 0.0023 -2.9014 0.00000071 
17 -0.0021 5.4218 0.00000084 
18 -0.0080 4.2675 0.00000001 
19 -0.0200 2.3603 0.00000068 
20 -0.0035 3.4451 -0.00000044 
21 0.0142 4.8766 -0.00000044 
22 -0.0171 7.1129 0.00000082 
X 0.0148 4.2595 -0.00000152 
Y -0.0040 5.3937 0.00000005 
Table 7.15. Coefficients for chromosome models for patient D. 
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chr 𝛽𝛽1 𝛽𝛽2 𝛽𝛽3 
1 0.0019 0.4059 0.00000012 
2 0.0140 -2.2165 0.00000066 
3 0.0023 3.8831 0.00000013 
4 0.0081 6.7147 0.00000009 
5 -0.0197 -5.9144 0.00000043 
6 0.0138 4.0495 0.00000075 
7 0.0187 2.9437 -0.00000072 
8 0.0127 8.1505 0.00000027 
9 0.0087 -5.4002 0.00000033 
10 0.0033 6.2483 0.00000059 
11 0.0191 1.8344 0.00000074 
12 -0.0079 3.8368 0.00000102 
13 -0.0147 -1.0476 0.00000054 
14 0.0080 -0.7254 -0.00000023 
15 -0.0154 2.5250 -0.00000002 
16 0.0073 -0.6750 0.00000067 
17 -0.0016 6.0702 0.00000011 
18 -0.0014 6.4145 -0.00000033 
19 -0.0041 0.9393 0.00000135 
20 -0.0042 3.8852 0.00000075 
21 0.0148 5.5249 0.00000020 
22 -0.0178 7.6082 -0.00000075 
X 0.0144 5.5756 -0.00000133 
Y 0.0007 4.0187 0.00000059 
Table 7.16. Coefficients for chromosome models for patient E. 
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chr 𝛽𝛽1 𝛽𝛽2 𝛽𝛽3 
1 0.0013 -1.8080 -0.00000024 
2 0.0140 -0.8890 -0.00000031 
3 0.0025 3.7933 -0.00000064 
4 0.0101 6.0363 0.00000093 
5 -0.0157 -5.1467 0.00000096 
6 0.0131 5.4381 0.00000094 
7 0.0067 3.8777 0.00000093 
8 0.0183 6.8689 -0.00000070 
9 0.0219 -5.3636 0.00000030 
10 -0.0082 6.2296 0.00000044 
11 0.0021 3.8518 0.00000038 
12 -0.0123 3.1948 0.00000086 
13 -0.0161 -0.6092 -0.00000002 
14 0.0145 -0.4893 0.00000091 
15 -0.0103 2.5162 -0.00000055 
16 0.0036 -2.8785 -0.00000054 
17 -0.0074 6.0751 0.00000016 
18 0.0011 4.9096 0.00000031 
19 -0.0068 1.4684 0.00000077 
20 0.0053 2.9407 0.00000085 
21 0.0109 5.0740 -0.00000079 
22 -0.0151 7.9485 -0.00000032 
X 0.0130 3.6375 0.00000014 
Y 0.0007 3.9946 -0.00000030 
Table 7.17. Coefficients for chromosome models for patient F. 
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chr 𝛽𝛽1 𝛽𝛽2 𝛽𝛽3 
1 -0.0013 -0.0143 0.00000090 
2 0.0104 -2.0696 -0.00000036 
3 0.0096 3.3256 0.00000011 
4 0.0070 6.3824 0.00000013 
5 -0.0026 -5.3594 -0.00000045 
6 0.0137 5.4012 0.00000101 
7 0.0051 2.8205 0.00000025 
8 0.0151 8.2805 -0.00000058 
9 0.0165 -5.7032 0.00000071 
10 0.0032 6.6396 0.00000035 
11 0.0055 3.3530 0.00000095 
12 0.0035 5.5225 -0.00000042 
13 -0.0128 -0.8615 0.00000077 
14 0.0095 -1.3463 -0.00000080 
15 -0.0031 0.7591 0.00000131 
16 0.0049 -0.7272 0.00000082 
17 0.0031 5.9467 0.00000026 
18 0.0026 4.4366 0.00000110 
19 -0.0190 2.3530 -0.00000035 
20 0.0047 4.5874 -0.00000040 
21 0.0160 4.3033 -0.00000043 
22 -0.0190 7.7892 0.00000057 
X 0.0126 3.1060 -0.00000125 
Y 0.0007 5.4127 0.00000069 
Table 7.18. Coefficients for chromosome models for patient G 
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chr 𝛽𝛽1 𝛽𝛽2 𝛽𝛽3 
1 0.0032 -0.3078 -0.00000059 
2 0.0012 -0.1699 -0.00000048 
3 0.0069 5.6587 0.00000034 
4 0.0071 5.6634 -0.00000021 
5 -0.0095 -5.7618 -0.00000061 
6 0.0096 5.0768 0.00000005 
7 0.0091 4.3699 0.00000022 
8 0.0166 7.2473 0.00000020 
9 0.0219 -6.1187 0.00000011 
10 0.0018 6.7467 0.00000037 
11 0.0184 2.8218 -0.00000042 
12 0.0037 4.5330 0.00000079 
13 -0.0176 -1.8377 0.00000106 
14 0.0113 0.1349 -0.00000049 
15 -0.0192 1.6409 0.00000095 
16 -0.0046 -0.7617 -0.00000046 
17 0.0013 6.2843 0.00000011 
18 -0.0074 4.9845 0.00000013 
19 -0.0075 0.7691 0.00000034 
20 -0.0062 3.9471 0.00000032 
21 0.0034 4.7239 -0.00000039 
22 -0.0194 6.4096 0.00000041 
X 0.0141 3.5085 -0.00000091 
Y 0.0013 5.1003 0.00000093 
Table 7.19. Coefficients for chromosome models for patient H 
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7.1.4 Comparison of performance of our model versus other algorithms 
In order to evaluate our framework better, we compared our proposed framework with 
three state-of-the-art algorithms which are Support Vector Machines using Sequential 
Minimal Optimization, Gaussian Process regression model and Radial Basis Function 
Network. The following paragraphs briefly explain them in more detail. 
SVMs (Support Vector Machines) is a well known technique widely used for 
classification and regression.  It is one of the most popular state-of-the-art algorithms 
which can be utilized to provide a model for linear and non-linear problems. 
Mathematically speaking, the SVM model can be interpreted as solving the optimization 
problem below: 
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Where ix  : training vectors.  
 w   : weight vectors.  
 ( )ixφ : kernel function 
 b: the bias.  
 ξ : parameter to handle over-fitting. 
Here we utilized one major implementation of SVM, which is the sequential minimal 
optimization (SMO) implementation to compare to the proposed framework. The 
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performance is given in figure 7.17. It shows that it performs worse than the proposed 
algorithm. In addition, there is a lot of variance in the performance of the SVM-based 
solution. The possible reason is the over fitting problem. More details can be found in 
[119].  
Gaussian Processes for Regression 
The Gaussian process for regression is well known model for machine-learning. It is a 
generalized form of the Gaussian probability distribution. Similar to the correspondent 
distribution, the Gaussian process for regression is determined by the covariance and 
mean function. The function here f(x) comes from just one sample from the actual 
distribution. More details on this method can be found in [120].  
Radial Basis Function  
It follows an artificial neural network approach which employs functions that are based 
on  a radial basis. Radial basis functions based on neuron arguments are the output of this 
network. For a given input x,  ,  the algorithm produces a scalar function, 
, given by: 
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Where 
N : number of neurons  (hidden layer) 
ic  : center vector of neuron i,  
ia : weight of neuron i  
For more details on this algorithm, we can refer to [121]. 
 
The comparison results are shown in Table 7.20 and Figure 7.17. For this, we compared 
the correlation coefficients achieved by each different algorithm and verified that our 
selected model had a better performance and stability across all chromosomes. We can 
observe that the Radial Basis Function Network shows the highest variance. This is very 
dangerous in the medical domain as the predicted values show high variability. The other 
two algorithms have a better performance when compared to the Radial Basis Function 
Network; however, they also still lower performance than our selected model and higher 
variance. Our model, on the other hand, is stable across all chromosomes showing more 
accurate predictions. 
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Chr 
Linear 
Regression 
Radial Basis 
Function 
Network 
Sequential 
Minimal 
Optimization GaussianProcess 
1 0.9412 0.4533 0.9389 0.9356 
2 0.9999 0.8452 0.9253 0.9235 
3 0.9994 0.3159 0.9993 0.9235 
4 0.9769 0.8627 0.9718 0.9741 
5 0.9475 0.4144 0.9448 0.9373 
6 0.9998 0.0806 0.9985 0.9909 
7 0.9826 0.5022 0.9383 0.9956 
8 0.9972 0.0616 0.9972 0.9235 
9 0.9403 0.0112 0.8055 0.9307 
10 0.9896 0.1312 0.9819 0.9827 
11 0.9565 0.4605 0.9192 0.9436 
12 0.9946 0.9368 0.9946 0.7254 
13 0.9999 0.4473 0.8715 0.9657 
14 1 0.1127 1 0.9973 
15 0.9995 0.957 0.9993 0.9762 
16 0.9609 0.0206 0.9609 0.8614 
17 0.9987 0.8142 0.9982 0.9142 
18 0.9914 0.969 0.9875 0.9654 
19 0.9885 0.9045 0.9829 0.9773 
20 0.9702 0.2325 0.9625 0.9611 
21 0.9959 0.3255 0.9958 0.9992 
22 0.9786 0.1466 0.7901 0.9334 
X 0.9922 0.0569 0.9892 0.9728 
Y 0.9992 0.8394 0.9986 0.9728 
Table 7.20. Comparison table for correlation coefficients for our model versus others. 
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Figure 7.17 Comparison of performance of our model versus others. 
7.1.5 Concluding Remarks 
The identification and classification of mutations in patients are centric topics in today’s 
cancer research. In this study, we first defined the problem of predicting the number of 
mutations on a chromosome for a certain patient, which is a fundamental problem in both 
research and clinical fields. Next, this problem is modeled mathematically as a linear 
regression problem. After applying a thorough analysis on each chromosome of each 
patient, we have the following observations: 
1. As shown in the detailed statistical analysis in terms of error, the 95% confidence 
interval of each of the error measurement metrics are computed. For example, the 
correlation coefficient, which indicates the degree of matching of the proposed 
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framework with real data, is 0.9816 0.009 with 95% confidence interval. In addition, 
our collaborator from medical domain thinks that the proposed framework achieves very 
good performance and opens new research opportunities for bioinformatics researchers 
and clinical doctors.  
2. The proposed framework is relatively stable across patients. By analyzing errors of 
each patient, it can be seen that the errors are close to each other across different patients. 
Since patients are selected randomly, this observation gives us the confidence that the 
proposed framework is relatively stable and robust. It can be applied on new data 
collected from new patients.  
3. In terms of the coefficients learned from different chromosomes on different 
patients, no significant global patterns are identified. This indicates that each individual 
patient has unique characteristic and it is hard to generalize a simple rule based strategy 
for all patients. On the other hand, the proposed framework which trains the linear 
regression model can adapt to each patient relatively well by representing the different 
characteristics of patients in the numerical weights gained from the model. This explains 
the reason why our framework achieves relatively stable performance across different 
patients. In addition, an observation is that the coefficient for the ChrToGenomeRatio 
feature is relatively small in all models, which indicate its’ contribution is limited. More 
features are going to be added to enhance the model further in the future.  
As we train the model with more longitudinal data, the estimation error should decrease. 
An example graph shown in the next Figure illustrates this statement. Additionally, as we 
collect more data points, in the future, we open the possibility to experiment other 
machine-learning algorithms as well. 
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Figure 7.18 Potential estimation error graph as more data is obtained. 
7.2 Prediction of location of mutations. 
Table 7.2 refers to the locations of mutations, both observed and predicted, for all 
chromosomes in patient UPN 933124.  Column two and three show the nucleotide 
positions of the mutations. Column four shows the name of the gene, if present in the 
region, in the case of observed mutations. Similarly, column five shows the name of the 
gene if present in the region corresponding to the predicted mutations. Not surprisingly, 
most of the areas containing the mutations (both observed and predicted) lie in the so-
called intergenic regions of the genome. It is worth noting that the areas of the genome 
transcriptionally active are reported to be just 1% of the whole genome [122]. Close to 
99% of the human genome does not code for proteins, and correspond to areas with either 
other known functionalities as regulation of gene expression (enhancers, promoters, 
inhibitors) or that do not have a defined function yet.  
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Chr 
Observed 
Location 
Location of the 
predicted mutation 
Gene or genetic 
region observed 
Gene or genetic  
region predicted 
1 107357719 107358018 INTERGENIC INTERGENIC 
1 179307551 179309065 INTERGENIC INTERGENIC 
1 218018901 218020628 INTERGENIC INTERGENIC 
2 184186967 184186891 INTERGENIC INTERGENIC 
2 213886052 213884438 SPAG16 SPAG16 
3 21310708 21307866 INTERGENIC INTERGENIC 
3 43135962 43138381 INTERGENIC INTERGENIC 
4 26362673 26362567 TBC1D19 TBC1D19 
5 22595465 22595335 CDH12 CDH12 
5 93857376 93859895 INTERGENIC INTERGENIC 
6 40467367 40464779 LRFN2 INTERGENIC 
6 95631430 95629374 INTERGENIC INTERGENIC 
7 85476859 85474442 INTERGENIC INTERGENIC 
7 120917535 120914752 LOC392979 LOC392979 
8 25022615 25022103 INTERGENIC INTERGENIC 
8 34167561 34165529 INTERGENIC INTERGENIC 
8 35476742 35478696 INTERGENIC INTERGENIC 
8 51256369 51253560 SNTG1 SNTG1 
9 36887024 36889733 PAX5 PAX5 
9 137816463 137818783 KCNT1 KCNT1 
11 23583427 23584671 INTERGENIC INTERGENIC 
11 40183906 40182763 LRRC4C LRRC4C 
12 9702101 9703657 LOC374443 INTERGENIC 
12 22283439 22281122 ST8SIA1 ST8SIA1 
13 60889651 60891444 INTERGENIC INTERGENIC 
13 92466026 92467721 INTERGENIC INTERGENIC 
14 47961450 47963585 INTERGENIC INTERGENIC 
102 
 
14 82608644 82607776 INTERGENIC INTERGENIC 
16 7941529 7943725 INTERGENIC INTERGENIC 
16 58050635 58052689 INTERGENIC INTERGENIC 
17 67861248 67859454 INTERGENIC INTERGENIC 
20 17261178 17262629 PCSK2 PCSK2 
20 58861532 58863711 INTERGENIC INTERGENIC 
21 23370033 23372348 INTERGENIC LOC100130310 
X 86570002 86570879 INTERGENIC INTERGENIC 
Table 7.21. Location of mutations, both observed and predicted, for patient UPN 933124. 
 
7.3 Accuracy discussion 
Table 7.3 shows the results of the analysis for the patient UPN 933124. It presents the 
total number of mutations per genome, number of matches, mismatches, and accuracy of 
the prediction. When the prediction lies within the same region of an observed mutation, 
it constitutes a match. Conversely, if the location for the prediction does not correspond 
to the location of an observed mutation, or if the area of the observed mutation is not 
predicted at all, it is considered a mismatch.  
We emphasize that the location of the prediction does not have to match the precise 
location of the observed mutation. Falling within the same gene boundaries is sufficient 
to classify it as a match. When the location of the mutation falls in an intergenic region 
(or a region devoid of a known functional activity) one criterion we use to classify it as a 
match, is that the prediction lies within less than 3000 nucleotides of the observed one on 
both directions. Although the distance of 3000 nucleotides may look arbitrary, to the best 
of our knowledge it is a reasonable assumption when there is no knowledge as to the 
functional features determined in such an intergenic region. 
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Matches 32 
Mismatches 3 
Total Mutations 35 
Relative Accuracy 91% 
Absolute Accuracy 76% 
Table 7.22. Summary of results for patient UPN 933124. 
 
With these criteria in mind, we came up with two accuracies. The first one is the 
"Relative Accuracy" which measures how many matches we had out of the predicted 
mutations we accounted for. For instance, in the case of the patient UPN 933124, we 
found out that even though the number of mutations at time of relapse was 42, we only 
predicted 35 mutations with 32 of them classified as matches. As a result, the accuracy 
was 91% (32/35). This accuracy is called "Relative Accuracy" because we are not 
considering the initial error given by the fact that the number of predicted mutations (35) 
was lower than the actual ones (42). 
The "Absolute Accuracy" incorporates this initial prediction error. Thus, its value is less 
than the "Relative Accuracy". For instance, for this patient, the initial accuracy for the 
number of predicted mutations was 83% and the "Relative Accuracy" was 91%, meaning 
that we really could only predict for this patient 83% (91%) of the total number of 
mutations correctly, giving us an accuracy of 76%. 
We carried out similar analysis for the seven remaining individuals. The accuracies are 
given as ranges with lower and upper values. This is explained by the fact that 
chromosomes models behave differently within the same individual, as well as, across 
patients. The verification of the predicted number of mutations versus the actual number 
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of mutations gave us an accuracy value within a range of 75 to 84%. Likewise, the 
verification of predicted locations of mutations versus actual locations of mutations 
resulted in an accuracy value within the range of 69 to 88%.  
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CHAPTER 8 
CONCLUSION 
 
8.1 Research summary 
The efforts and techniques used in this thesis represent the best methods we know to date 
in identifying meaningful mutational changes in leukemias that can help predict the 
following:  1.) responses to therapy, 2.) patients at increased risk of developing 
recurrences or progression of disease before and after treatment, 3.) driver mutations, 4.) 
passenger mutations, 5.) and evaluation of new potential druggable targets. 
The n (# of patients) of 8 used in this study is actually a fundamental strength of the 
proposed study for the following reasons.  Most research examining mutational spectra 
within cancers rely solely on snapshots, i.e. the presence or absence of mutations in 
tumors at one discrete time point.  Though this information is valuable, it tells us nothing 
regarding the evolution of the disease.  In particular, several high profile papers in the last 
2-3 years have taken advantage of the TCGA database to mine solid tumors for mutations 
in these snapshots – work out of robust genome sequencing groups including from 
Washington University, St Louis (Science, 2012) and Harvard.  All of these papers 
appear in very high end journals but use data from only one time point.  A recent paper in 
Nature (2013) offered similar comparisons of such samples.  It is more straightforward to 
have n’s approaching 100-200+ patients for these less complex situations. 
The gold standard really should be to get genomic mutational data for tumors from 
patients across their disease course over multiple time points.  This longitudinal 
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information represents the most valuable and relevant data in truly determining how to 
cure patients of disease.  A paper in the very important journal Cell from early 2013 
evaluated CLL patient tumor mutational spectra [123].  This work came out of a 
collaboration between the BROAD Institute of MIT and Harvard and Dana Farber Cancer 
Center, highly renowned for their leukemia patient volume.  They had only snapshots of 
140 or so patients for which they were able to identify mutation frequency.  However, as 
the reviewers and authors acknowledge, they had a more valuable data set – 18 patients 
for which they had longitudinal mutational spectra from 2 time points – before and after 
chemotherapy.  Only sequencing of coding areas were used in this effort.  With 18 
patients, they were able to make conclusions regarding the evolution of the CLL disease 
course, helping oncologists further understand the disease process to improve the lives of 
the patients.  All agreed that this 18 patient data set was in many ways more valuable than 
the 140 patient snapshot mutational database.  Additionally, NCI has recently made it a 
priority to better understand unique findings in smaller data series if the samples are 
difficult to come by.  Longitudinal mutational data is very difficult to come by and 
perhaps offers the most important clues to disease processes. 
In our work, we have been able to collect 8 valuable longitudinal mutational data from 
leukemia patients before and after multiple therapies.  This collection may represent one 
of the largest series compiled in a robust manner.  Our sequencing data is of the entire 
genome, unlike the coding only analysis from the Cell paper. Finally, our data 
approximates locations of mutational hot spots, which is very important because many 
changes in leukemia tumor DNA represent large frame shift alterations, deletions, 
insertions, or translocations.   
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8.2 Final statistical remarks 
We analyze the mutations in the longitudinal dimension at the chromosome level. From 
this perspective, one patient actually provides  24 samples. Therefore, instead of 8 
samples, we actually test our algorithm using 24x8 = 192 samples. This amount of data is 
significant in terms of regular statistical and data  mining tasks. Compared with peer 
studies in the cancer research domain as mentioned by our collaborator in biomedical 
field, our number of patients as well as the measurements of mutations at multiple time 
shots for each patient are more significant than the recent published papers in Nature and 
Science. Even though the data samples are actually enough for significance, we still draw 
the conclusion prudently. In our statistical analysis of errors, the routing approach of 
estimating the confidence interval is using the normal distribution assumption. If that 
assumption is used here, the variation of our estimation is even smaller. However, given 
the current sample size, we still use the student-T distribution assumption to estimate 
errors. By using this, we draw a conservative conclusion. Given this observation, we 
would expect the performance of our algorithm on new data sets would be better.  
As the cost of performing the whole genome sequencing is relatively expensive 
nowadays, it is infeasible to carry out the whole genome sequencing for the cancer 
patient routinely. On the other hand, the information of mutations in chromosomes at the 
molecular level gives precious information about patients and can guide clinical doctors 
in practice. The gap exists here should be addressed in order to improve the quality of 
treatments for patients. In addition, each patient has his/her individual characteristics 
which need to be considered. The proposed work provides a study from a relatively novel 
angle. First and foremost, a linear regression model is fit using three input features, which 
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are “RatioStdMean”, “RatioGivenChr” and “ChrToGenomRation”. Since the number of 
patients’ visitings to hospitals is limited, the number of samples from each patient is 
sparse. Our model can take care of this issue since the model can be fit using features 
from as few as two time points. In addition, a model is built on each chromosome for 
each patient, this model adapts to each patient’s specialty and therefore is relatively 
robust. From the clinical point of view, the predictions of mutations can be meaningful 
for clinical doctors from the following two perspectives. First, the mutation frequency 
and patterns of the chromosomes of patients are useful information for medical doctors to 
make decision on the effectiveness of treatment and adjust treating strategy. Second, the 
mutation information can be further utilized as a factor to associate to classifying 
different types of cancer. A recent study in Nature actually shows that the mutation 
frequency has correlations with the different types of breast cancer. From this point of 
view, the mutation frequency predicted of each chromosome and the profile of mutation 
frequency predicted for each patient will offer the information for doctors to classify the 
cancer types and adjust treatment strategy accordingly. All these clinical significance 
motivates us for this research. Based on the success of applying the linear regression 
model in this study, we will extend the current work to a more broad problem, that is, we 
will try to fit a model across patients. Using this model, we can make predictions for the 
possibilities of mutations on a chromosome of a new patient based on the data collected 
from patients in our database. We believe this model, if successfully constructed, will 
provide more significant tools for medical practitioners. 
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8.3 Foundation for further discoveries.  
Our concepts may have tremendous impact on a number of important areas relevant to 
future cancer care of patients.  Specifically, our ideas may:  
 
1. Increase our ability to predict which leukemia patients will develop relapses thru 
treatment. 
2. Help predict which high risk patients (those having received chemotherapy for other 
cancers, patients on immunosuppressive therapy for organ transplantation, etc.) may 
develop leukemia down the road. 
3. Help distinguish driver versus passenger mutations in leukemia.  
4. Help identify mutations that may develop during leukemogenesis that are druggable 
targets. 
5. Ultimately help leukemia patients have longer survival. 
 
None of these results are trivial, especially in the setting of leukemias.  There is a 
significant advantage to our work.  Our models appear to be quite robust and relevant to 
leukemia disease states.  We have employed longitudinal data sets from actual leukemia 
patients that we have used to build our models and validate them.  The rationale behind 
our efforts is also convincing.  Identification of approximate areas of deletion, insertion, 
and other mutations will be quite valuable as we begin to realize that most mutations in 
malignancy may not just be driven by single nucleotide polymorphisms. 
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8.4 Application of our framework in the treatment of patients by clinical oncologists 
It is quite clear that our work will provide high impact understanding of the natural 
evolution of basal leukemia mutation rates and development before chemotherapy use 
and more importantly the state of mutations at the time of leukemia relapse. A vital 
question is how this data will be beneficial or relevant to a medical oncologist's practice 
on a day to day basis.  From the initial applications of the predictive modeling of future 
mutation rates, we expect physician's to develop key information when they first 
diagnose a patient's leukemia, i.e. will there be an increase in mutation rate in the specific 
patient's leukemia at the time of relapse, will there be hotspots in the genome for this 
greater mutation rate that is associated with druggable targets, will there be at the time of 
relapse a completely different set of mutations (explaining why the patient's tumor 
relapses), etc.  At the time of relapse, a medical oncologist has several decisions to make: 
keep the patient  on the same leukemia drug but add a second drug, increase the levels of 
the drug in circulation, or change the drug completely.  With the predictive mutation 
modeling, the medical oncologist can know in advance to potentially be prepared to take 
one of the above courses based on where the mutations may appear and in what 
frequency at the time of relapse. This knowledge, in the form of an algorithm of 
chemotherapy use, would be of great necessity in allowing medical oncologist's to 
optimize timing and response to patient leukemia relapses. 
Finally, the greatest utility that the predictive model from this work may provide in the 
long run to medical oncologists and cancer specialists is a novel unbiased approach to 
genomically organize leukemias based on their natural evolution of mutation 
development.  Historically, for many decades, leukemias were characterized (ALL, 
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AML, CLL, CML) purely by histopathologic and cytopathologic analyses.  This data was 
the only information used by physicians to decide how to treat patients with leukemias.  
This was a limited data set, however.  With the identification of mutations associated 
with each type of leukemia, we are now incorporating this latter information into medical 
management practices.  The use of targeted therapies including Gleevec was predicated 
on knowing if a leukemia possessed a bcr-abl mutation. 
Despite the advances, we are still only making treatment decisions on a static evaluation 
of mutations at the time of diagnosis.  The predictive algorithm provided in this work 
may open a totally new avenue by which cancer specialists can organize similar behaving 
leukemias into independent groups based on functional outcomes.  Potentially, we would 
be able to characterize a leukemia as highly aggressive, aggressive, or minimally 
aggressive based on the prediction of mutation frequency/location at the time of relapse.  
Highly aggressive leukemias would be predicted to have greater mutation rates and sites 
at relapse, suggesting an earlier time to relapse.  Minimally aggressive lesions would 
potentially have predicted lower rates of mutation and relapse at later time points.  The 
power of this effort is that we would be taking into account all mutational changes (which 
may have distinct interactions), not just hypothesized driver mutations, to describe the 
ultimate output behavior of  leukemias, before and after chemotherapy.  A medical 
oncologist would be able to accurately predict how a patient with leukemia will do if he 
knows from the onset the likelihood of high or low mutation rates, predicting for highly 
or minimally aggressive disease.  At the very least, with the creation of these "clades" or 
new ways to group leukemias based on functional outcomes, we will get a better sense of 
how many distinct subgroups or entities of leukemias are seen in the public.  At the most, 
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medical oncologists will be prepared to be more or less aggressive with changing 
chemotherapy regimens based on how the specific patient's leukemia is categorized.  
Staying ahead of the relapse conditions that promote increased mutational frequency by 
combining chemotherapies or changing the time of chemotherapy usage may ultimately 
improve progression free and overall survival, the gold standard for any cancer patient 
outcome. 
 
8.5 Some potential enhancements. 
Our framework has been built using Java technology and utilizes an external library 
called Weka for its prediction model. At the present time, we are using a linear regression 
algorithm provided by Weka. As we collect more patients’ data, we will be able to 
perform more sophisticated prediction algorithms such as neural networks. Similarly as 
Weka evolves and more algorithms are included in this library, our framework will be 
able to extend its functionality by invoking these new features from the API. Thus, our 
architecture is flexible for future changes and/or enhancements. 
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APPENDICES 
 
Patients Data before prediction  
HIPAA limitations are not involved here as a problem since, as mentioned earlier, we are 
using the published data from Ding et al publication [13]. 
 
Prediction results for predicting number of mutations at each chromosome for 
every patient. 
On the following pages, we can see the results of our framework when predicting the 
number of mutations to occur at each chromosome for each patient.  
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Data for Patient: A  
 
Chromosome Observed Mutations 
Predicted 
Mutations 
1 1 1 
2 2 1 
5 1 1 
6 2 2 
7 2 2 
8 1 1 
10 1 1 
11 1 0 
12 2 1 
13 2 1 
15 2 2 
18 1 1 
19 1 1 
22 1 1 
X 2 2 
Total 22 18 
Accuracy: 81.82% 
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Data for Patient: B  
 
Chromosome Observed Mutations 
Predicted 
Mutations 
1 7 5 
2 10 7 
3 4 3 
4 8 6 
5 5 4 
6 7 5 
7 6 5 
8 2 2 
9 2 2 
10 7 5 
11 4 3 
12 4 3 
13 4 3 
14 3 2 
15 2 2 
16 6 5 
17 6 4 
18 3 2 
19 3 2 
20 2 2 
21 3 2 
22 2 1 
X 3 2 
Y 2 2 
Total 105 79 
Accuracy 75.24% 
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Data for Patient: C  
 
Chromosome Observed Mutations 
Predicted 
Mutations 
1 4 3 
2 2 2 
3 3 2 
4 1 1 
5 2 2 
6 2 2 
7 3 2 
8 5 4 
9 2 2 
11 3 2 
12 3 2 
13 2 2 
14 2 2 
16 3 2 
17 1 1 
20 2 2 
21 1 1 
X 1 1 
Total 42 35 
Accuracy 83.73% 
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 Data for Patient: D  
 
Chromosome Observed Mutations 
Predicted 
Mutations 
2 1 1 
3 1 1 
4 1 1 
5 1 1 
6 1 1 
8 2 1 
10 3 1 
16 2 2 
17 1 1 
18 1 1 
X 1 1 
Total 15 12 
Accuracy 80.00% 
 
119 
 
Data for Patient: E  
 
Chromosome Observed Mutations 
Predicted 
Mutations 
1 9 7 
2 15 11 
3 2 2 
4 12 9 
5 7 5 
6 7 5 
7 5 4 
8 3 2 
9 3 2 
10 4 3 
11 3 2 
12 3 2 
13 3 2 
14 2 2 
15 1 1 
16 2 1 
17 4 3 
18 4 3 
20 2 1 
21 2 2 
22 1 1 
X 5 4 
Total 99 74 
Accuracy 74.75% 
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Data for Patient: F  
 
Chromosome Observed Mutations 
Predicted 
Mutations 
1 5 4 
2 14 11 
3 6 5 
4 6 4 
5 3 2 
6 10 8 
7 5 4 
8 4 3 
9 6 5 
10 3 2 
11 5 4 
12 4 3 
13 4 3 
14 4 3 
15 2 2 
17 3 2 
18 5 4 
19 2 2 
20 2 1 
21 1 1 
22 1 1 
X 4 3 
Y 1 1 
Total 100 78 
Accuracy 78.00% 
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Data for Patient: G  
 
Chromosome Observed Mutations 
Predicted 
Mutations 
1 1 1 
2 1 1 
4 1 1 
7 1 1 
9 1 1 
12 1 0 
13 1 1 
14 1 1 
16 1 0 
18 1 1 
19 1 1 
21 1 1 
Total 12 10 
Accuracy 83.33% 
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 Data for Patient: H  
 
Chromosome Observed Mutations 
Predicted 
Mutations 
1 5 4 
2 7 5 
3 3 2 
4 5 4 
5 5 4 
6 6 4 
7 1 1 
8 3 2 
9 3 2 
10 3 2 
11 3 2 
12 5 4 
14 2 2 
15 1 1 
16 2 2 
17 1 1 
18 1 1 
20 1 1 
22 1 1 
X 7 6 
Total 65 51 
Accuracy 78.46% 
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Prediction results with summarized data including actual and predicted locations 
Below we have the results for our prediction indicating the actual location of the mutation 
and the predicted one. Similarly, we show the actual gene involved and the predicted 
gene involved. We also have a column called "difference" to indicate the error of our 
estimations. 
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PATIENT A 
 
 
Chr RelapseLocation PredictedLocation  Difference RelapseGene   PredictedGene 
 
1 105905196  105903822   -1374  INTERGENIC-REGION INTERGENIC-REGION 
2 103478832  103478707   -125  LOC728815   LOC728815 
5 117968777  117966963   -1814  INTERGENIC-REGION INTERGENIC-REGION 
6 117330941  117333649   2708  RFXDC1   RFXDC1 
6 148467197  148465214   -1983  INTERGENIC-REGION INTERGENIC-REGION 
7 120243306  120241310   -1996  TSPAN12   TSPAN12 
7 141400429  141399010   -1419  MGAM    MGAM 
8 6610082   6611300   1218  INTERGENIC-REGION INTERGENIC-REGION 
10 36300363  36297857   -2506  INTERGENIC-REGION INTERGENIC-REGION 
12 36181843  36180237   -1606  INTERGENIC-REGION INTERGENIC-REGION 
13 77038729  77037998   -731  SCEL    SCEL 
15 35693981  35696254   2273  INTERGENIC-REGION INTERGENIC-REGION 
15 96495601  96496583   982  INTERGENIC-REGION INTERGENIC-REGION 
18 67016988  67019842   2854  INTERGENIC-REGION INTERGENIC-REGION 
19 15919303  15919555   252  INTERGENIC-REGION INTERGENIC-REGION 
22 46504211  46505232   1021  INTERGENIC-REGION INTERGENIC-REGION 
X 7449501   7449885   384  INTERGENIC-REGION INTERGENIC-REGION 
X 89181903  89179381   -2522  LOC100130134   INTERGENIC-REGION 
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PATIENT B 
 
 
Chr RelapseLocation PredictedLocation  Difference RelapseGene   PredictedGene 
 
1 18730737  18731528   791  INTERGENIC-REGION INTERGENIC-REGION 
1 22831628  22830967   -661  INTERGENIC-REGION INTERGENIC-REGION 
1 89433568  89435914   2346  GBP4    GBP4 
1 119892131  119890585   -1546  INTERGENIC-REGION INTERGENIC-REGION 
1 164527242  164529039   1797  INTERGENIC-REGION INTERGENIC-REGION 
2 4951026   4948442   -2584  INTERGENIC-REGION INTERGENIC-REGION 
2 18760057  18760752   695  INTERGENIC-REGION INTERGENIC-REGION 
2 41983085  41981902   -1183  INTERGENIC-REGION INTERGENIC-REGION 
2 52337923  52337545   -378  INTERGENIC-REGION INTERGENIC-REGION 
2 53366757  53368759   2002  INTERGENIC-REGION INTERGENIC-REGION 
2 114769762  114770766   1004  INTERGENIC-REGION INTERGENIC-REGION 
2 137663285  137664050   765  THSD7B   THSD7B 
3 97423737  97422285   -1452  INTERGENIC-REGION INTERGENIC-REGION 
3 148730059  148727347   -2712  INTERGENIC-REGION INTERGENIC-REGION 
3 174114325  174114486   161  SPATA16   SPATA16 
4 17783989  17783525   -464  INTERGENIC-REGION INTERGENIC-REGION 
4 18912208  18913676   1468  INTERGENIC-REGION INTERGENIC-REGION 
4 22759171  22761274   2103  LOC643751   LOC643751 
4 31779477  31778159   -1318  INTERGENIC-REGION INTERGENIC-REGION 
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4 103369618  103367568   -2050  INTERGENIC-REGION INTERGENIC-REGION 
4 132134033  132136548   2515  INTERGENIC-REGION INTERGENIC-REGION 
5 27542961  27545241   2280  INTERGENIC-REGION INTERGENIC-REGION 
5 73771482  73772512   1030  INTERGENIC-REGION INTERGENIC-REGION 
5 95272060  95274071   2011  ELL2    ELL2 
5 154221315  154224153   2838  CNOT8    CNOT8 
6 11556067  11553580   -2487  INTERGENIC-REGION INTERGENIC-REGION 
6 55539300  55536902   -2398  HMGCLL1   HMGCLL1 
6 89788729  89786090   -2639  INTERGENIC-REGION INTERGENIC-REGION 
6 94679810  94677079   -2731  INTERGENIC-REGION INTERGENIC-REGION 
6 98935123  98933684   -1439  INTERGENIC-REGION INTERGENIC-REGION 
7 13405534  13402864   -2670  INTERGENIC-REGION INTERGENIC-REGION 
7 25018068  25018936   868  INTERGENIC-REGION INTERGENIC-REGION 
7 101609893  101612118   2225  CUX1    CUX1 
7 101701575  101703838   2263  CUX1    CUX1 
7 116559358  116559716   358  ST7    ST7 
8 73514564  73511684   -2880  INTERGENIC-REGION INTERGENIC-REGION 
8 76476615  76478306   1691  INTERGENIC-REGION INTERGENIC-REGION 
9 7987216   7987623   407  INTERGENIC-REGION INTERGENIC-REGION 
9 11413168  11415994   2826  INTERGENIC-REGION INTERGENIC-REGION 
10 21774153  21775175   1022  INTERGENIC-REGION INTERGENIC-REGION 
10 24053538  24052997   -541  KIAA1217   KIAA1217 
10 37158144  37159499   1355  INTERGENIC-REGION INTERGENIC-REGION 
10 52992328  52992927   599  PRKG1    PRKG1 
10 100679446  100679728   282  HPSE2    HPSE2 
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11 26915201  26913996   -1205  INTERGENIC-REGION INTERGENIC-REGION 
11 27181250  27184040   2790  INTERGENIC-REGION INTERGENIC-REGION 
11 29982645  29982170   -475  INTERGENIC-REGION INTERGENIC-REGION 
12 61776966  61778798   1832  INTERGENIC-REGION INTERGENIC-REGION 
12 72620513  72623219   2706  INTERGENIC-REGION INTERGENIC-REGION 
12 82288736  82290376   1640  INTERGENIC-REGION INTERGENIC-REGION 
13 35326695  35328951   2256  DCLK1    DCLK1 
13 53087241  53089305   2064  INTERGENIC-REGION INTERGENIC-REGION 
13 56856089  56856249   160  INTERGENIC-REGION INTERGENIC-REGION 
14 28018404  28019485   1081  INTERGENIC-REGION INTERGENIC-REGION 
14 69464698  69464658   -40  SMOC1   SMOC1 
15 39166414  39169210   2796  INOC1    INOC1 
15 88432939  88433205   266  IDH2    IDH2 
16 26547638  26546235   -1403  INTERGENIC-REGION INTERGENIC-REGION 
16 30758901  30759255   354  LOC100129191  LOC100129191 
16 70613693  70614741   1048  DHODH    DHODH 
16 76093122  76094288   1166  INTERGENIC-REGION INTERGENIC-REGION 
16 80961258  80960904   -354  INTERGENIC-REGION INTERGENIC-REGION 
17 7334949   7337664   2715  POLR2A   POLR2A 
17 10874727  10875744   1017  INTERGENIC-REGION INTERGENIC-REGION 
17 27701282  27698390   -2892  MIRN632   INTERGENIC-REGION 
17 34007774  34005119   -2655  SNIP    SNIP 
18 23266563  23267169   606  FLJ45994   FLJ45994 
18 36665237  36665827   590  INTERGENIC-REGION INTERGENIC-REGION 
19 32989705  32990040   335  LOC642290   LOC642290 
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19 41696897  41697985   1088  ZNF260   ZNF260 
20 17900146  17902446   2300  C20orf72   C20orf72 
20 49730834  49729040   -1794  ATP9A    ATP9A 
21 26930860  26928939   -1921  INTERGENIC-REGION INTERGENIC-REGION 
21 27215461  27214843   -618  ADAMTS5   ADAMTS5 
22 18266604  18269168   2564  TXNRD2   TXNRD2 
X 24850996  24849917   -1079  POLA1    POLA1 
X 33727134  33727059   -75  INTERGENIC-REGION INTERGENIC-REGION 
Y 8487910   8485327   -2583  INTERGENIC-REGION INTERGENIC-REGION 
Y 16302321  16300318   -2003  INTERGENIC-REGION INTERGENIC-REGION 
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PATIENT C 
 
 
Chr RelapseLocation PredictedLocation  Difference RelapseGene   PredictedGene 
 
 
1 107357719  107358018   299  INTERGENIC-REGION INTERGENIC-REGION 
1 179307551  179309065   1514  INTERGENIC-REGION INTERGENIC-REGION 
1 218018901  218020628   1727  INTERGENIC-REGION INTERGENIC-REGION 
2 184186967  184186891   -76  INTERGENIC-REGION INTERGENIC-REGION 
2 213886052  213884438   -1614  SPAG16   SPAG16 
3 21310708  21307866   -2842  INTERGENIC-REGION INTERGENIC-REGION 
3 43135962  43138381   2419  INTERGENIC-REGION INTERGENIC-REGION 
4 26362673  26362567   -106  TBC1D19   TBC1D19 
5 22595465  22595335   -130  CDH12    CDH12 
5 93857376  93859895   2519  INTERGENIC-REGION INTERGENIC-REGION 
6 40467367  40464779   -2588  LRFN2    INTERGENIC-REGION 
6 95631430  95629374   -2056  INTERGENIC-REGION INTERGENIC-REGION 
7 85476859  85474442   -2417  INTERGENIC-REGION INTERGENIC-REGION 
7 120917535  120914752   -2783  LOC392979   LOC392979 
8 25022615  25022103   -512  INTERGENIC-REGION INTERGENIC-REGION 
8 34167561  34165529   -2032  INTERGENIC-REGION INTERGENIC-REGION 
8 35476742  35478696   1954  INTERGENIC-REGION INTERGENIC-REGION 
8 51256369  51253560   -2809  SNTG1    SNTG1 
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9 36887024  36889733   2709  PAX5    PAX5 
9 137816463  137818783   2320  KCNT1    KCNT1 
11 23583427  23584671   1244  INTERGENIC-REGION INTERGENIC-REGION 
11 40183906  40182763   -1143  LRRC4C   LRRC4C 
12 9702101   9703657   1556  LOC374443   INTERGENIC-REGION 
12 22283439  22281122   -2317  ST8SIA1   ST8SIA1 
13 60889651  60891444   1793  INTERGENIC-REGION INTERGENIC-REGION 
13 92466026  92467721   1695  INTERGENIC-REGION INTERGENIC-REGION 
14 47961450  47963585   2135  INTERGENIC-REGION INTERGENIC-REGION 
14 82608644  82607776   -868  INTERGENIC-REGION INTERGENIC-REGION 
16 7941529   7943725   2196  INTERGENIC-REGION INTERGENIC-REGION 
16 58050635  58052689   2054  INTERGENIC-REGION INTERGENIC-REGION 
17 67861248  67859454   -1794  INTERGENIC-REGION INTERGENIC-REGION 
20 17261178  17262629   1451  PCSK2    PCSK2 
20 58861532  58863711   2179  INTERGENIC-REGION INTERGENIC-REGION 
21 23370033  23372348   2315  INTERGENIC-REGION LOC100130310 
X 86570002  86570879   877  INTERGENIC-REGION INTERGENIC-REGION 
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PATIENT D 
 
 
Chr RelapseLocation PredictedLocation  Difference RelapseGene   PredictedGene 
 
 
2 1119223   1118090   -1133  SNTG2    SNTG2 
3 183065520  183064291   -1229  INTERGENIC-REGION INTERGENIC-REGION 
4 185168709  185166707   -2002  STOX2    STOX2 
5 162177435  162174604   -2831  INTERGENIC-REGION INTERGENIC-REGION 
6 93462438  93461387   -1051  INTERGENIC-REGION INTERGENIC-REGION 
8 3293986   3295797   1811  CSMD1   CSMD1 
10 84453341  84452336   -1005  NRG3    NRG3 
16 61747374  61747530   156  INTERGENIC-REGION INTERGENIC-REGION 
16 62989048  62988198   -850  INTERGENIC-REGION INTERGENIC-REGION 
17 22045352  22042405   -2947  INTERGENIC-REGION INTERGENIC-REGION 
18 42887822  42889970   2148  HDHD2   HDHD2 
X 121434334  121431398   -2936  INTERGENIC-REGION INTERGENIC-REGION 
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PATIENT E 
 
 
Chr RelapseLocation PredictedLocation  Difference RelapseGene   PredictedGene 
 
 
1 44944905  44945092   187  MGC33556   MGC33556 
1 56758799  56755847   -2952  PPAP2B   PPAP2B 
1 62329867  62328205   -1662  INADL    INADL 
1 80186452  80184770   -1682  INTERGENIC-REGION INTERGENIC-REGION 
1 162652104  162653254   1150  INTERGENIC-REGION INTERGENIC-REGION 
1 193708003  193707136   -867  INTERGENIC-REGION INTERGENIC-REGION 
1 193987679  193985578   -2101  INTERGENIC-REGION INTERGENIC-REGION 
2 16261487  16259478   -2009  INTERGENIC-REGION INTERGENIC-REGION 
2 79424915  79425833   918  INTERGENIC-REGION INTERGENIC-REGION 
2 81008756  81008969   213  INTERGENIC-REGION INTERGENIC-REGION 
2 83365574  83367876   2302  INTERGENIC-REGION INTERGENIC-REGION 
2 121062191  121062952   761  INTERGENIC-REGION INTERGENIC-REGION 
2 121512897  121514104   1207  INTERGENIC-REGION INTERGENIC-REGION 
2 125156383  125157880   1497  CNTNAP5   CNTNAP5 
2 125314902  125317068   2166  CNTNAP5   CNTNAP5 
2 132126629  132126964   335  INTERGENIC-REGION INTERGENIC-REGION 
2 136723675  136726085   2410  INTERGENIC-REGION INTERGENIC-REGION 
2 151445176  151443514   -1662  INTERGENIC-REGION INTERGENIC-REGION 
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3 1887762   1887661   -101  INTERGENIC-REGION INTERGENIC-REGION 
3 175001625  175001097   -528  NLGN1    NLGN1 
4 20084861  20083013   -1848  SLIT2    SLIT2 
4 30772025  30773500   1475  INTERGENIC-REGION INTERGENIC-REGION 
4 31398117  31399931   1814  INTERGENIC-REGION INTERGENIC-REGION 
4 93687647  93687017   -630  GRID2    GRID2 
4 96814327  96813949   -378  INTERGENIC-REGION INTERGENIC-REGION 
4 105371233  105370352   -881  INTERGENIC-REGION INTERGENIC-REGION 
4 111770497  111769372   -1125  PITX2    PITX2 
4 137387938  137387568   -370  INTERGENIC-REGION INTERGENIC-REGION 
4 137620857  137618498   -2359  INTERGENIC-REGION INTERGENIC-REGION 
5 21248739  21250383   1644  INTERGENIC-REGION INTERGENIC-REGION 
5 22482248  22483703   1455  CDH12    CDH12 
5 22495984  22494710   -1274  CDH12    CDH12 
5 22744459  22743789   -670  CDH12    CDH12 
5 45004983  45004149   -834  INTERGENIC-REGION INTERGENIC-REGION 
6 20902367  20899506   -2861  CDKAL1   CDKAL1 
6 50040060  50040552   492  INTERGENIC-REGION INTERGENIC-REGION 
6 66897241  66900208   2967  INTERGENIC-REGION INTERGENIC-REGION 
6 87126465  87126336   -129  INTERGENIC-REGION INTERGENIC-REGION 
6 94961835  94961835   0  INTERGENIC-REGION INTERGENIC-REGION 
7 13598141  13595372   -2769  INTERGENIC-REGION INTERGENIC-REGION 
7 47290289  47289020   -1269  TNS3    TNS3 
7 68773299  68774264   965  AUTS2    AUTS2 
7 147006720  147009358   2638  CNTNAP2   CNTNAP2 
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8 4788849   4787918   -931  CSMD1   CSMD1 
8 23806889  23805931   -958  INTERGENIC-REGION INTERGENIC-REGION 
9 12110080  12111967   1887  INTERGENIC-REGION INTERGENIC-REGION 
9 28701959  28704866   2907  LINGO2   LINGO2 
10 52502567  52503933   1366  PRKG1    PRKG1 
10 55997651  55997740   89  PCDH15   PCDH15 
10 56392820  56391742   -1078  INTERGENIC-REGION INTERGENIC-REGION 
11 61267618  61269091   1473  DAGLA   DAGLA 
11 64146939  64144929   -2010  NRXN2   NRXN2 
12 83033586  83033124   -462  INTERGENIC-REGION INTERGENIC-REGION 
12 93956009  93955103   -906  NR2C1    NR2C1 
13 57139096  57136968   -2128  PCDH17   PCDH17 
13 62444093  62442127   -1966  INTERGENIC-REGION INTERGENIC-REGION 
14 46290472  46290215   -257  INTERGENIC-REGION INTERGENIC-REGION 
14 105609184  105611251   2067  INTERGENIC-REGION INTERGENIC-REGION 
15 76418530  76417893   -637  INTERGENIC-REGION INTERGENIC-REGION 
16 26981824  26984046   2222  INTERGENIC-REGION INTERGENIC-REGION 
17 3004064   3003465   -599  OR1P1P   INTERGENIC-REGION 
17 13501009  13499899   -1110  INTERGENIC-REGION INTERGENIC-REGION 
17 31379333  31379326   -7  INTERGENIC-REGION INTERGENIC-REGION 
18 5846231   5846301   70  INTERGENIC-REGION INTERGENIC-REGION 
18 29678931  29677804   -1127  INTERGENIC-REGION INTERGENIC-REGION 
18 37355263  37356895   1632  INTERGENIC-REGION INTERGENIC-REGION 
20 12364137  12361276   -2861  INTERGENIC-REGION INTERGENIC-REGION 
21 21114306  21113277   -1029  INTERGENIC-REGION INTERGENIC-REGION 
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21 27426278  27427344   1066  INTERGENIC-REGION INTERGENIC-REGION 
22 49192948  49194052   1104  SAPS2    SAPS2 
X 23373203  23375572   2369  INTERGENIC-REGION INTERGENIC-REGION 
X 88250191  88250874   683  INTERGENIC-REGION INTERGENIC-REGION 
X 97368810  97370397   1587  INTERGENIC-REGION INTERGENIC-REGION 
X 116745872  116748160   2288  INTERGENIC-REGION INTERGENIC-REGION 
 
PATIENT F 
 
 
Chr RelapseLocation PredictedLocation  Difference RelapseGene   PredictedGene 
 
 
1 92405867  92406858   991  INTERGENIC-REGION INTERGENIC-REGION 
1 92814472  92813494   -978  EVI5    EVI5 
1 96583536  96582384   -1152  LOC100132258   LOC100132258 
1 111864509  111865538   1029  ADORA3   ADORA3 
2 18769914  18768780   -1134  INTERGENIC-REGION INTERGENIC-REGION 
2 22359545  22361976   2431  INTERGENIC-REGION INTERGENIC-REGION 
2 50857536  50855234   -2302  NRXN1   NRXN1 
2 66491986  66494804   2818  INTERGENIC-REGION INTERGENIC-REGION 
2 83614631  83612098   -2533  INTERGENIC-REGION INTERGENIC-REGION 
2 84115889  84116667   778  INTERGENIC-REGION INTERGENIC-REGION 
2 126135788  126137404   1616  INTERGENIC-REGION INTERGENIC-REGION 
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2 167238182  167237566   -616  INTERGENIC-REGION INTERGENIC-REGION 
2 172352355  172354666   2311  SLC25A12   SLC25A12 
2 173346781  173345732   -1049  RAPGEF4   RAPGEF4 
2 184179988  184177573   -2415  INTERGENIC-REGION INTERGENIC-REGION 
3 43881260  43883533   2273  INTERGENIC-REGION INTERGENIC-REGION 
3 46659901  46659510   -391  INTERGENIC-REGION INTERGENIC-REGION 
3 96394238  96395455   1217  INTERGENIC-REGION INTERGENIC-REGION 
3 139135471  139135228   -243  INTERGENIC-REGION INTERGENIC-REGION 
3 180628899  180631315   2416  GNB4    GNB4 
4 27863801  27863829   28  INTERGENIC-REGION INTERGENIC-REGION 
4 65007608  65008077   469  INTERGENIC-REGION INTERGENIC-REGION 
4 123096911  123098079   1168  INTERGENIC-REGION INTERGENIC-REGION 
4 132093722  132093932   210  INTERGENIC-REGION INTERGENIC-REGION 
5 23368167  23369740   1573  INTERGENIC-REGION INTERGENIC-REGION 
5 56807873  56807941   68  INTERGENIC-REGION INTERGENIC-REGION 
6 126353   129210    2857  INTERGENIC-REGION INTERGENIC-REGION 
6 9844264   9845543   1279  INTERGENIC-REGION INTERGENIC-REGION 
6 68090304  68090598   294  INTERGENIC-REGION INTERGENIC-REGION 
6 77430774  77430160   -614  INTERGENIC-REGION INTERGENIC-REGION 
6 86029763  86029106   -657  INTERGENIC-REGION INTERGENIC-REGION 
6 94768681  94769618   937  INTERGENIC-REGION INTERGENIC-REGION 
6 109550234  109548825   -1409  C6orf182   C6orf182 
6 112245364  112244333   -1031  FYN    FYN 
7 13880370  13882510   2140  INTERGENIC-REGION INTERGENIC-REGION 
7 39559272  39559474   202  INTERGENIC-REGION INTERGENIC-REGION 
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7 55323684  55322359   -1325  INTERGENIC-REGION INTERGENIC-REGION 
7 104147320  104147939   619  LHFPL3   LHFPL3 
8 63596628  63594602   -2026  NKAIN3   NKAIN3 
8 72857393  72854439   -2954  INTERGENIC-REGION INTERGENIC-REGION 
8 118381845  118381895   50  INTERGENIC-REGION INTERGENIC-REGION 
9 454456   453609    -847  DOCK8   DOCK8 
9 80165699  80166263   564  INTERGENIC-REGION INTERGENIC-REGION 
9 110146992  110149359   2367  INTERGENIC-REGION INTERGENIC-REGION 
9 118884413  118884831   418  ASTN2    ASTN2 
9 126126705  126128087   1382  NEK6    NEK6 
10 2683387   2682198   -1189  INTERGENIC-REGION INTERGENIC-REGION 
10 6584079   6585226   1147  PRKCQ   PRKCQ 
11 10203546  10200736   -2810  SBF2    SBF2 
11 40438832  40440545   1713  INTERGENIC-REGION INTERGENIC-REGION 
11 55428174  55430431   2257  OR5W1P   INTERGENIC-REGION 
11 87891301  87893310   2009  GRM5    GRM5 
12 38297190  38294864   -2326  ABCD2    ABCD2 
12 44240246  44239417   -829  INTERGENIC-REGION INTERGENIC-REGION 
12 79813281  79812561   -720  LIN7A    LIN7A 
13 55417148  55419652   2504  INTERGENIC-REGION INTERGENIC-REGION 
13 70427767  70426376   -1391  INTERGENIC-REGION INTERGENIC-REGION 
13 81090538  81090305   -233  INTERGENIC-REGION INTERGENIC-REGION 
14 31667574  31668810   1236  ARHGAP5   ARHGAP5 
14 33154434  33153004   -1430  NPAS3    NPAS3 
14 56091064  56089536   -1528  INTERGENIC-REGION INTERGENIC-REGION 
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15 40851227  40850495   -732  TTBK2    TTBK2 
15 79991574  79992556   982  INTERGENIC-REGION INTERGENIC-REGION 
17 39843379  39841478   -1901  GPATCH8   GPATCH8 
17 45343100  45344560   1460  INTERGENIC-REGION INTERGENIC-REGION 
18 5053185   5051558   -1627  INTERGENIC-REGION INTERGENIC-REGION 
18 5938070   5938026   -44  INTERGENIC-REGION INTERGENIC-REGION 
18 11401121  11401673   552  INTERGENIC-REGION INTERGENIC-REGION 
18 39337589  39338647   1058  INTERGENIC-REGION INTERGENIC-REGION 
19 5893322   5895546   2224  RANBP3   RANBP3 
19 43341487  43339217   -2270  SIPA1L3   SIPA1L3 
20 13210300  13213050   2750  C20orf82   C20orf82 
21 42042422  42039541   -2881  RIPK4    RIPK4 
22 47687788  47685465   -2323  INTERGENIC-REGION INTERGENIC-REGION 
X 93658417  93660653   2236  INTERGENIC-REGION INTERGENIC-REGION 
X 104960175  104962733   2558  NRK    NRK 
X 111343447  111345610   2163  ZCCHC16   ZCCHC16 
Y 7721445   7723250   1805  INTERGENIC-REGION INTERGENIC-REGION 
139 
 
 
PATIENT G 
 
 
Chr RelapseLocation PredictedLocation  Difference RelapseGene   PredictedGene 
 
 
1 79586157  79587862   1705  INTERGENIC-REGION INTERGENIC-REGION 
2 147777631  147775238   -2393  INTERGENIC-REGION INTERGENIC-REGION 
4 142853353  142851908   -1445  IL15    IL15 
7 19896920  19895976   -944  INTERGENIC-REGION INTERGENIC-REGION 
9 25271855  25270748   -1107  INTERGENIC-REGION INTERGENIC-REGION 
13 91834507  91836278   1771  GPC5    GPC5 
14 25426007  25427524   1517  INTERGENIC-REGION INTERGENIC-REGION 
18 6593666   6595162   1496  INTERGENIC-REGION INTERGENIC-REGION 
19 1339089   1339688   599  NDUFS7   NDUFS7 
21 30692169  30694843   2674  INTERGENIC-REGION INTERGENIC-REGION 
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PATIENT H 
 
 
Chr RelapseLocation PredictedLocation  Difference RelapseGene   PredictedGene 
 
 
1 28395117  28396128   1011  INTERGENIC-REGION INTERGENIC-REGION 
1 55348624  55345772   -2852  USP24    USP24 
1 80466160  80466553   393  INTERGENIC-REGION INTERGENIC-REGION 
1 104112500  104114609   2109  INTERGENIC-REGION INTERGENIC-REGION 
2 4358173   4355389   -2784  INTERGENIC-REGION INTERGENIC-REGION 
2 14285436  14284784   -652  INTERGENIC-REGION INTERGENIC-REGION 
2 106766704  106769370   2666  INTERGENIC-REGION INTERGENIC-REGION 
2 119250670  119251555   885  INTERGENIC-REGION INTERGENIC-REGION 
2 155081458  155083587   2129  INTERGENIC-REGION INTERGENIC-REGION 
3 1799169   1800181   1012  INTERGENIC-REGION INTERGENIC-REGION 
3 20956204  20956611   407  INTERGENIC-REGION INTERGENIC-REGION 
4 46955181  46952231   -2950  GABRB1   GABRB1 
4 149316450  149317894   1444  NR3C2    NR3C2 
4 150025553  150024817   -736  INTERGENIC-REGION INTERGENIC-REGION 
4 158256256  158253511   -2745  GLRB    GLRB 
5 15823239  15821488   -1751  FBXL7    FBXL7 
5 29515287  29512926   -2361  INTERGENIC-REGION INTERGENIC-REGION 
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5 104466311  104465825   -486  INTERGENIC-REGION INTERGENIC-REGION 
5 113840798  113840471   -327  KCNN2   KCNN2 
6 9855937   9853948   -1989  INTERGENIC-REGION INTERGENIC-REGION 
6 38352606  38355567   2961  BTBD9    BTBD9 
6 96112105  96114311   2206  INTERGENIC-REGION INTERGENIC-REGION 
6 98495373  98496129   756  INTERGENIC-REGION INTERGENIC-REGION 
7 141689176  141686364   -2812  TRB@    TRB@ 
8 2568547   2567553   -994  INTERGENIC-REGION INTERGENIC-REGION 
8 31261001  31259469   -1532  INTERGENIC-REGION INTERGENIC-REGION 
9 75985332  75984229   -1103  INTERGENIC-REGION INTERGENIC-REGION 
9 82308637  82311378   2741  INTERGENIC-REGION INTERGENIC-REGION 
10 22510615  22508285   -2330  INTERGENIC-REGION INTERGENIC-REGION 
10 23382721  23380837   -1884  INTERGENIC-REGION INTERGENIC-REGION 
11 26651719  26654173   2454  SLC5A12   SLC5A12 
11 82054955  82055363   408  INTERGENIC-REGION INTERGENIC-REGION 
12 3464622   3467549   2927  INTERGENIC-REGION INTERGENIC-REGION 
12 11883491  11884936   1445  ETV6    ETV6 
12 43022207  43021782   -425  TMEM117   TMEM117 
12 72136658  72138814   2156  INTERGENIC-REGION INTERGENIC-REGION 
14 20830373  20828361   -2012  RPGRIP1   RPGRIP1 
14 43499979  43498964   -1015  INTERGENIC-REGION INTERGENIC-REGION 
15 76806819  76809320   2501  LOC646934   LOC646934 
16 59519213  59518116   -1097  INTERGENIC-REGION INTERGENIC-REGION 
16 84039293  84040691   1398  INTERGENIC-REGION INTERGENIC-REGION 
17 22057902  22059434   1532  INTERGENIC-REGION INTERGENIC-REGION 
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18 13846987  13844333   -2654  INTERGENIC-REGION INTERGENIC-REGION 
20 43469052  43469585   533  SYS1-DBNDD2  SYS1-DBNDD2 
22 24752889  24753260   371  MYO18B   MYO18B 
X 6998334   6996308   -2026  HDHD1A   HDHD1A 
X 104572042  104570775   -1267  IL1RAPL2   IL1RAPL2 
X 114186799  114188858   2059  INTERGENIC-REGION INTERGENIC-REGION 
X 121017574  121014781   -2793  INTERGENIC-REGION INTERGENIC-REGION 
X 127355500  127356514   1014  INTERGENIC-REGION INTERGENIC-REGION 
X 127868848  127869973   1125  INTERGENIC-REGION INTERGENIC-REGION 
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